


A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response

Graphical abstract



Authors

Lily Xu, Kaitlyn Saunders, Shao-Po Huang, ..., Evanthia T. Roussos Torres, Lin Xu, Isaac S. Chan

Correspondence

isaac.chan@utsouthwestern.edu

In brief

Xu, Saunders, and Huang et al. generate a large, single-cell RNA sequencing dataset of the breast tumor microenvironment. They use this real-world data atlas to further characterize NK cells and create InteractPrint. InteractPrint is a method that accounts for tumor heterogeneity and accurately predicts response to immunotherapy across breast cancer subtypes.

Highlights

- Generated a large single-cell RNA sequencing primary breast tumor atlas
- Identified six new NK cell subsets in the breast tumor microenvironment
- Determined how cancer cell heterogeneity influences immune response in the breast TME
- InteractPrint predicts patient response to immunotherapy across subtypes



Article

A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response

Lily Xu,^{1,2,9} Kaitlyn Saunders,^{1,2,9} Shao-Po Huang,^{1,2,9} Hildur Knutsdottir,³ Kenneth Martinez-Algarin,^{1,2} Isabella Terrazas,^{1,2} Kenian Chen,⁴ Heather M. McArthur,^{1,2} Julia Maués,⁵ Christine Hodgdon,⁵ Sangeetha M. Reddy,^{1,2} Evanthis T. Roussos Torres,⁶ Lin Xu,⁴ and Isaac S. Chan^{1,2,7,8,10,*}

¹Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA

²Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA

³Department of Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA

⁴Quantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA

⁵GRASP Cancer, Baltimore, MD, USA

⁶Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

⁷Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

⁸Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA

⁹These authors contributed equally

¹⁰Lead contact

*Correspondence: isaac.chan@utsouthwestern.edu

<https://doi.org/10.1016/j.xcrm.2024.101511>

SUMMARY

We present an integrated single-cell RNA sequencing atlas of the primary breast tumor microenvironment (TME) containing 236,363 cells from 119 biopsy samples across eight datasets. In this study, we leverage this resource for multiple analyses of immune and cancer epithelial cell heterogeneity. We define natural killer (NK) cell heterogeneity through six subsets in the breast TME. Because NK cell heterogeneity correlates with epithelial cell heterogeneity, we characterize epithelial cells at the level of single-gene expression, molecular subtype, and 10 categories reflecting intratumoral transcriptional heterogeneity. We develop InteractPrint, which considers how cancer epithelial cell heterogeneity influences cancer-immune interactions. We use T cell InteractPrint to predict response to immune checkpoint inhibition (ICI) in two breast cancer clinical trials testing neoadjuvant anti-PD-1 therapy. T cell InteractPrint was predictive of response in both trials versus PD-L1 (AUC = 0.82, 0.83 vs. 0.50, 0.72). This resource enables additional high-resolution investigations of the breast TME.

INTRODUCTION

Breast cancer is the most common cancer among women.¹ The development of breast cancer is driven by both cancer epithelial cell-intrinsic factors^{2–4} and the tumor microenvironment (TME).^{5,6} The medical treatment of breast cancer therefore targets these diverse cell populations and includes traditional chemotherapy, targeted agents inhibiting cancer cell hormone receptors, kinases, cell cycle entry, and immune cell modulators. To further improve these therapies, a deeper understanding of the cellular and molecular composition of breast tumors is required.

Single-cell RNA sequencing (scRNA-seq) technology has been applied to better characterize tumor microenvironments. For breast cancer, several scRNA-seq studies have been performed to identify key immune, cancer cell, and stromal populations of the breast TME.^{7–14} These studies provided insight into molecular phenotypes of cancer cells, multiple immune popula-

tions, and other stromal cells. However, each study was limited by the number of samples and cells analyzed. This poses challenges to performing comprehensive analysis of heterogeneous cell populations and their cellular interactions in the TME.

For example, natural killer (NK) cells are innate lymphoid immune cells critical to anti-tumor defense. In breast cancer, tumor-infiltrating NK cells are rare,^{15–19} representing 1%–6% of total tumor cells in published scRNA-seq datasets of primary breast tumors.^{7–9,11–14} Their cytotoxic activity is regulated by a series of functionally activating and inactivating receptors. After tumor exposure, the balance of NK cell-activating and -inactivating receptors can change, and they can lose their cytotoxic activity or proliferative capacity or even become tumor promoting.^{20–22} Because of the small numbers of NK cells processed in most human studies, scRNA-seq analyses of NK cells are often underpowered to capture their distinct functional phenotypes. Additionally, breast cancer is known to have substantial






Figure 1. Integrated scRNA-seq dataset of primary breast cancer identifies six NK cell subsets in breast cancer

(A) Brief overview of the processing and integration pipeline for 8 primary breast cancer datasets.

(B) UMAP visualization of 236,363 cells across 119 samples from 88 patients analyzed by scRNA-seq.

(C) UMAP visualization showing major subsets of natural killer (NK) cells.

(D) Bubble heatmap showing expression of upregulated differentially expressed genes for each major NK cell subset (Bonferroni-adjusted $p < 0.05$).

(legend continued on next page)

heterogeneity within the tumor of a single patient and between patients of a clinical subtype.^{23,24} Therefore, comprehensive analysis of cancer epithelial cell heterogeneity requires large and diverse datasets with adequate numbers of samples from all clinical breast cancer subtypes.

In this study, we created an integrated scRNA-seq atlas of the breast TME, consisting of 236,363 cells from 119 biopsy samples across 8 publicly available datasets.^{7–14} This resource enables separation of cell populations within primary breast tumors and robust characterization of cellular heterogeneity at the single-cell level. This integrated dataset is more statistically powerful than traditional meta-analyses of original source datasets and enables evaluation of correlations with clinical features. We used this resource to define immune and cancer epithelial cell heterogeneity along with their interactions. It is the first, to our knowledge, to define NK cell subsets in breast cancer and provides evidence that cancer epithelial cell heterogeneity influences immune interactions and response to anti-PD-1 therapy. This dataset provides a comprehensive resource to better understand the composition of the breast TME.

RESULTS

An integrated scRNA-seq dataset of breast cancer samples reveals distinct NK cell subsets that exhibit diverse functional characteristics

To develop a high-resolution atlas of the breast TME, we analyzed scRNA-seq data from 119 samples collected from primary tumor biopsies of 88 patients across 8 publicly available breast cancer datasets (Figures 1A and S1A–S1C; Data S1).^{7–14} After processing each dataset separately to filter out low-quality cells and doublets, we integrated a total of 236,363 cells across all clinical subtypes and a wide spectrum of clinical features (Data S1). We assessed batch effect to ensure no cluster was driven by a single dataset or technology (STAR Methods; Figures S1D–S1L and S2A–S2I). Cell types were identified by taking the top call resulting from a three-step process that labeled clusters based on a signature score of canonical cell markers, marker count coupled with average expression, and greatest average expression of the marker genes alone (Data S2; STAR Methods). Uniform manifold approximation and projection (UMAP) visualization showed clustering of cells by lineage. Immune and stromal cell populations clustered together across clinical subtypes, while epithelial cells showed separation by subtype (Figures 1B and S1F), which is consistent with other

studies.^{11,13} For all datasets, single-cell copy number variant (CNV) profiles were estimated to distinguish cancer from normal epithelial cells (Figures S3A–S3D).

Because the number of cells in this dataset permits statistically powered analysis of rare immune cell populations in human breast cancers, we first leveraged the integrated dataset to better characterize the heterogeneity of NK cells. While NK cells are key mediators of anti-tumor control, our understanding of their varied phenotype and function in the breast TME is limited and incomplete. To our knowledge, there are no prior studies that dissect NK cell subsets in the human breast TME. To address this gap, we re-clustered NK cells from the integrated dataset (Figure S4A). Unsupervised graph-based clustering uncovered 6 clusters of NK cells, designated NK-0 through NK-5 (Figures 1C, S4B, and S4C).

Differential gene expression analysis between clusters revealed upregulated genes defining each NK subset (Figures 1D and S4D; Table 1; Data S3; STAR Methods). NK-0 and NK-2 express high levels of *FCGR3A* (CD16) and cytolytic molecules (granzymes and *PRF1*), which suggests that they are similar to CD56^{dim} NK cells.^{25–29} NK-0 is enriched for *KLRC2*, *ETS1*, and effector genes (*GZMH* and *CCL5*), which closely resembles gene expression profiles described previously for “memory-like” NK cells.²⁵ NK-2 is defined by increased expression of cytotoxicity-related genes (*GZMA*, *GZMB*, *PRF1*, and *SPON2*) and *S1PR5*, which has been described previously in CD56^{dim} bone marrow NK cells.²⁵ NK-4 is predominated by genes involved in interferon signaling (*IFI6* and *ISG15*), suggesting that this subset may be influenced by interferon-high tumor microenvironments and consists of activated NK cells involved in the direct anti-tumor response.³⁰ NK-3 cells appear to have features of tissue-resident NK cells, with upregulated expression of *SELL*, *IL7R*, and *GZMK* as well as reduced expression of cytolytic genes and *FCGR3A* (CD16).³¹ In contrast, genes of inactivity and reduced cytotoxicity were upregulated in clusters NK-1 and NK-5. Most notably, NK-1 was marked by genes related to the *NR4A* family,^{32,33} *JUN*, *FOS*, and *DUSP1*. *NR4A* is a family of orphan nuclear receptors that act as transcription factors; they are thought to negatively regulate T cell cytotoxicity³² and have been described as marking specific NK cells with reduced interferon gamma production.^{29,33} NK-5 had reduced expression of cytolytic genes and *FCGR3A* (CD16) and increased expression of *KLRC1* and *CD96*, which are inactivators of NK cell activity.^{34,35} To further define the function of NK cell subsets, we performed gene set enrichment analysis of individual clusters, which confirmed their functional phenotypes (Figure S4E).

(E) Boxplot showing expression of the rNK cell signature in each NK cell subset. NK-1 was significantly different from all other clusters (Kruskal-Wallis $p < 0.0001$, with post hoc Dunn test p values shown; **** $p < 0.0001$).

(F) MA plot of differentially expressed genes between rNK and non-rNK cells (Bonferroni-adjusted $p < 0.05$).

(G) Boxplot showing the expression level of the rNK signature by clinical subtype. No significant difference was found between subtypes (Kruskal-Wallis $p > 0.05$).

(H) Circos plots showing representative predictive receptor-ligand pairs between rNK cells and all cancer epithelial cells separated by clinical subtype. Shared receptors across all subtypes are colored in red.

(I) Boxplot showing the Pearson correlations of rNK signature gene expression in reprogrammed NK (rNK) cells compared with non-rNK cells versus rNK cells compared with rNK cells (across all clinical subtypes of breast cancer). Pearson correlations between rNK cells and rNK cells are higher than those between rNK cells and non-rNK cells (two-sided Wilcoxon test, **** $p < 0.0001$).

(J) Scatterplot showing the Pearson correlation of age and proportion of rNK cells by sample ($p < 0.01$).

(K) Kaplan-Meier plot showing worse clinical outcome in breast cancer patients with high expression of the rNK cell gene signature (log rank test, $p < 0.05$).

(L) Bar plot showing relative proportions of NK subsets across tumor samples and clinical subtypes.

See also Figures S1–S5 and Data S1 and S4.

Table 1. Marker genes for 6 NK cell subsets

NK subset	Gene
NK-0	FCGR3A
NK-0	PRF1
NK-0	FGFBP2
NK-0	GZMH
NK-0	ETS1
NK-1	NR4A1
NK-1	NR4A2
NK-1	DUSP1
NK-1	DUSP2
NK-1	FOS
NK-1	JUN
NK-2	FCGR3A
NK-2	PRF1
NK-2	FGFBP2
NK-2	GZMA
NK-2	GZMB
NK-2	CXCF1
NK-2	SPON2
NK-2	CX3CR1
NK-2	S1PR5
NK-3	GZMK
NK-3	SELL
NK-3	IL7R
NK-3	LTB
NK-4	ISG15
NK-4	IFI6
NK-4	IFIT3
NK-4	IFI44L
NK-5	CCL5
NK-5	HLA-DRB1
NK-5	KLRC1
NK-5	CD74
NK-5	MYADM
NK-5	HSPE1

See also [Data S3](#).

Reprogrammed NK cells are most similar to the NK-1 subset and are observed in patient samples independent of subtype

Previously in *ex vivo* and mouse models, we observed that NK cells can be “reprogrammed” after exposure to malignant mammary epithelial cells to promote tumor outgrowth.^{20,21} To determine the human significance of this finding, we first generated a signature of mouse reprogrammed NK (rNK) cells based on an experiment²⁰ comparing the transcriptomes of healthy NK cells with tumor-exposed NK cells that we found to be tumor promoting and reprogrammed (Figure S5A). We next converted the original signature to the human analog (Figure S5B; Table 2) and applied it to the NK cell subsets. NK-1 scored significantly higher for the rNK signature than all other NK cell subsets ($p < 0.0001$)

(Figure 1E). Differential gene expression analysis of rNK cells compared with non-rNK cells revealed that the *NR4A* family (*NR4A1*, *NR4A2*, and *NR4A3*), *FOS*, *JUN*, and *DUSP1* were among the most differentially expressed genes (Figure 1F; Data S4; STAR Methods), similar to the transcriptional profile of the NK-1 subset.

To test whether rNK cells were associated with a specific breast cancer subtype, we examined the expression of rNK cells across clinical subtypes. We found no significant differences in rNK cell expression across all subtypes ($p > 0.05$, $n = 3,720$ NK cells total) (Figures 1G and S5C). Additionally, we found shared receptor-ligand pairs between NK cells and cancer epithelial cells across all subtypes (Figure 1H), including *LGALS3_SPN*, *RPS19_ICAM1*, and *HSP90B1_TNFRSF1B*. Further, the average Pearson correlation in gene expression levels between rNK cells was greater than between rNK and non-rNK cells ($p < 0.0001$) (Figures 1I and S5D). Together, these findings demonstrate that rNK cells are not defined by specific breast cancer subtype biology but suggest that a shared but still unknown mechanism contributes to NK cell reprogramming.

To further investigate the clinical significance of rNK cells, we observed that higher expression of rNK cells correlates with older age ($R = 0.33$, $p < 0.01$) (Figure 1J). Survival analysis was performed on patients in The Cancer Genome Atlas (TCGA) breast cancer cohort, and we first confirmed that age was not a confounder of this analysis (Figure S5E). Given the limitations of applying the rNK cell signature to bulk RNA-seq samples from TCGA, which include a substantial fraction of non-NK cells, only samples with a relatively high fraction of tumor-infiltrating NK cells were selected for analysis (STAR Methods). Increased expression of the rNK cell signature in tumors with a high fraction of NK cells correlates with worse overall survival ($p < 0.05$) (Figures 1K and S5F).

We then asked whether NK cell subsets were uniformly expressed across individuals and breast cancer subtypes. To answer this question, we characterized the degree of NK cell heterogeneity across patients in the integrated dataset. We observed remarkable heterogeneity in the proportions of NK cell subsets across patients (Figure 1L). Additionally, no NK cell subset was driven by a single patient, and all NK cell subsets were present across each breast cancer clinical subtype. However, NK cell subset heterogeneity as quantified using ROGUE analysis was observed to be significantly higher in certain clinical subtypes than others (Figure S5G). While there have been multiple reports of NK cell subsets in other cancers,^{28,29} none have yet explored the diversity of NK cell subsets within individual patient samples. Our findings provide further evidence of the diverse phenotypes of NK cells within individual primary breast tumors.

Individual breast tumors have varying degrees of cancer epithelial cell heterogeneity

Because we observed that NK cell heterogeneity is associated with certain clinical subtypes of breast cancer (Figure 1L), we reasoned that heterogeneity within breast cancer subtypes would be important when further characterizing the breast TME. We then used our dataset to explore the heterogeneity of cancer epithelial cells at different resolutions: at the level of

Table 2. rNK cell signature with upregulated and downregulated genes

Upregulated rNK genes	Downregulated rNK genes
ABCA1	AHRR
ALOX12	ALDH1B2
CALD1	ASB2
CAVIN2	ASNS
CCL4	ATF5
CLU	AVIL
CMKLR1	BCAT1
CR2	CARS1
CX3CR1	CDH1
DTX1	CDKN1A
DUSP1	CEMIP2
F5	CHAC1
FAM81A	CISH
FOS	CLBA1
FOSB	COX6A2
GAS2L1	CXCR6
GFRA2	EXYL1
GP6	FMNL2
HEATR9	GPT2
HES1	HMOX1
ITGAX	HPGDS
JUN	ISG20
KLRG1	ITGA1
LTBP1	LGALS3
MID1	LHFPL2
MPIG6B	ME1
NHSL2	MTHFD2
NR4A1	NEK6
NR4A2	NQO1
NR4A3	OSBPL1A
NYLK	OSGIN1
PARVB	PACSLN1
PLXNA4	PMEPA1
RASGRP2	PPP2R2C
RHPN1	PYCR1
SCD	RN7SL1
SLC6A4	SCN3B
THBS1	SH3PXD2B
TMTC1	SLC1A4
TNFAIP3	SLC6A9
TUBB1	SLC7A3
VWF	SLC7A5
XDH	SNORA23
	SSTR2
	TBC1D16
	TRIB3
	ZNF503

See also [Data S4](#).

single gene expression, molecular subtypes, and then 10 categories of cancer epithelial cells that reflect intratumoral transcriptional heterogeneity (ITTH).

Cancer epithelial cells are well known to demonstrate substantial intertumoral and intratumoral heterogeneity in primary breast tumors at the single-gene level.^{8,9,13,14,23,24} For example, heterogeneous expression of therapeutic targets could have clinical implications. Newer anti-HER2 and anti-TROP2 agents have shown benefit in patients across heterogeneous RNA and protein expression of their targets.^{36,37} This highlights an opportunity to better understand *ERBB2* (HER2) and *TACSTD2* (TROP2) expression heterogeneity in cancer epithelial cells using transcriptomics data. In contrast to bulk RNA-seq, which aggregates expression levels across all cell types and thus offers limited resolution for studying intratumoral heterogeneity,³⁸ the integrated dataset can be used to evaluate *ERBB2* and *TACSTD2* heterogeneity in cancer epithelial cells at the single-cell level across tumor samples. To do so, epithelial cells in the integrated dataset were re-clustered and re-integrated to account for technology-driven batch effects (Figures S6A–S6C). Cancer epithelial cells were distinguished from normal epithelial cells (Figures S3A and S3B). Consistent with prior studies,^{11,13} epithelial cells demonstrated stratification by patient (Figure S6A).

Previous bulk RNA-seq and immunohistochemistry (IHC) studies have reported expression of the *ERBB2* gene or HER2 protein in up to 70% of HER2-negative breast tumors.^{39,40} We detect *ERBB2* expression in 92% of samples independent of clinical subtype at the single-cell level (Figures 2A and S6D). For *TACSTD2*, we similarly observed notable heterogeneity (Figures 2B and S6E). In particular, *TACSTD2* expression was observed across all subtypes in 94% of samples. This provides additional evidence at single-cell resolution of what has been previously described in bulk RNA-seq and IHC studies, which report TROP2 positivity in 50%–93% of breast cancer samples.^{41–43} Interestingly, the proportion of *ERBB2*^{Hi} and *ERBB2*^{Med} cells and *TACSTD2*^{Hi} and *TACSTD2*^{Med} cells also varied between samples, reflecting heterogeneous RNA expression at the cellular level. We next asked how other clinically relevant target genes were related to *ERBB2* expression. We found that *PIK3CA*, *ERBB3*, and *FGFR* expression was highest in *ERBB2*^{Hi} cells (Figure 2C). In contrast, *TACSTD2* and *CD274* expression levels were highest in *ERBB2*^{Med} cells and notably lower in *ERBB2*^{Hi} cells. Upon analysis of target genes related to *TACSTD2*, we found that *EGFR*, *CDK*, and *NTRK* expression was elevated in *TACSTD2*^{Hi} cells (Figure 2D). *ERBB2*, *ERBB3*, *PIK3CA*, and *AR* expression was highest in *TACSTD2*^{Med} cells. Additionally, we observed that *TACSTD2*^{Med} cells highly express *NECTIN2*, a ligand related to *TIGIT*, which hints at potential synergy with anti-TROP2 therapeutics and immune checkpoint inhibition.

Next, we characterized the heterogeneity of molecular features between *ERBB2*^{Hi}, *ERBB2*^{Med}, and *ERBB2*^{Lo} populations. We performed gene set enrichment analysis for the *ERBB2* and *TACSTD2* groups to further characterize function (Figures S6F and S6G) and differential gene expression analyses between the groups (Figures 2E, S6F, and S6G). Of the upregulated genes for *ERBB2*^{Hi} cells, 47 genes have been shown to be direct interactors with *ERBB2* (Data S5). Differentially expressed genes in *ERBB2*^{Med} cells compared with *ERBB2*^{Hi} and *ERBB2*^{Lo}




Figure 2. Cancer epithelial cells demonstrate substantial ITTH

(A) Bar plot showing proportions of $ERBB2^{Hi}$, $ERBB2^{Med}$, and $ERBB2^{Lo}$ cells by sample.

(B) Bar plot showing proportions of $TACSTD2^{Hi}$, $TACSTD2^{Med}$, and $TACSTD2^{Lo}$ cells by sample.

(C) Heatmap of Z-scored average expression of clinically actionable targets in $ERBB2^{Hi}$, $ERBB2^{Med}$, and $ERBB2^{Lo}$ cells.

(D) Heatmap of Z-scored average expression of clinically actionable targets in $TACSTD2^{Hi}$, $TACSTD2^{Med}$, and $TACSTD2^{Lo}$ cells.

(E) MA plot showing differentially expressed genes between $ERBB2^{Hi}$ vs. $ERBB2^{Med}$ and $ERBB2^{Lo}$ cells (Bonferroni-adjusted $p < 0.05$).

(F) MA plot showing differentially expressed genes between $TACSTD2^{Hi}$ vs. $TACSTD2^{Med}$ and $TACSTD2^{Lo}$ cells (Bonferroni-adjusted $p < 0.05$).

(G) Boxplot showing the proportion of $ERBB2$ -expressing cells per sample by nodal status (two-sided Wilcoxon test, $p > 0.05$).

(H) Boxplot showing the proportion of $TACSTD2$ -expressing cells per sample by nodal status (two-sided Wilcoxon test, $p < 0.05$).

(I) Percentage of cancer epithelial cells by molecular subtype, sorted by sample score by the ROGUE metric.

(J) Plot showing discordance in predicted heterogeneity by molecular subtype and by ROGUE metric by sample. Samples with $>50\%$ difference between the normalized ROGUE metric and the maximum percentage of cells within the sample that belonged to a single molecular subtype are classified as discordant. See also Figures S6 and S7 and Data S5 and S6.

cells may provide insight into molecular features associated with $ERBB2$ heterogeneity and HER2-low tumors (Figures 2E, S6H, and S6I). For instance, *CEACAM6*,⁴⁴ *DUSP6*,⁴⁵ and *ITGB6*⁴⁶ were found to be upregulated in in $ERBB2^{Med}$ cells, which is consistent with prior reports of their expression in HER2+ cancer cells (Figure 2E). For $TACSTD2^{Hi}$, $TACSTD2^{Med}$, and $TACSTD2^{Lo}$

cells, differential gene expression analyses (Figures 2F, S6J, and S6K; Data S6) identified *KRT14* and *KRT17* as significantly upregulated genes in $TACSTD2^{Hi}$ cells. These genes have been implicated as markers for highly metastatic breast cancer cells.⁴⁷ When assessing for correlation with clinical features, the proportion of $ERBB2$ -expressing cells ($ERBB2^{Hi}$ or $ERBB2^{Med}$) within

Table 3. Gene lists consisting of 100 genes for 10 GEs

GE1	GE2	GE3	GE4	GE5	GE6	GE7	GE8	GE9	GE10
AC090498-1	ALDH3B2	A2M	ANLN	AIF1	ADIRF	AC093001-1	ADIRF	AC093001-1	AGR2
AC105999-2	ALOX15B	ACTA2	ANP32E	ALOX5AP	ANAPC11	ADIRF	AFF3	ADIRF	APOD
ADIRF	APOD	ACTG2	ARL6IP1	ANXA1	ATP5ME	AGR2	ALCAM	AGR2	AREG
AGR2	AZIN1	ANGPTL4	ASF1B	APOC1	AZGP1	AGR3	ANKRD30A	AGR3	AZGP1
AGR3	B2M	ANXA1	ASPM	APOE	BLVRB	ANKRD37	ANXA2	APOD	B2M
ALDH2	BNIP3	APOD	ATAD2	AREG	BST2	APOD	AR	AQP1	BST2
ANKRD30A	C1orf21	APOE	AURKA	C1ORF162	CALM1	AQP3	ARFGEF3	AQP5	BTG2
ARL6IP1	CALD1	BGN	BIRC5	C1QA	CCND1	ARC	ASAH1	AREG	C15ORF48
ARMT1	CALU	C6ORF15	BUB1B	C1QB	CD9	AREG	ATP1B1	ASCL1	CCL20
ATAD2	CAPG	CALD1	CCNB1	C1QC	CETN2	ATF3	AZGP1	AZGP1	CD74
AZGP1	CD24	CALML5	CCNB2	CARD16	CISD3	AZGP1	BTG1	BMPR1B	CEBPD
BATF	CD59	CAV1	CDC20	CCL3	CLDN7	BAMBI	CD59	C15ORF48	CHI3L1
BMPR1B	CD74	CAVIN1	CDC6	CCL4	COX6C	BTG1	CDK12	CALML5	CHI3L2
BST2	CD99	CAVIN3	CDCA3	CCL5	CRABP2	BTG2	CEBPD	CCL28	CP
BTG2	CDKN2B	CCL28	CDCA8	CD2	CRACR2B	C15ORF48	CLDN3	CD55	CRISP3
C15ORF48	CFD	CCN2	CDK1	CD27	CRIP1	CALML5	CLDN4	CEACAM6	CSTA
CCDC74A	CKB	CD24	CDKN2A	CD37	CRIP2	CCDC74A	CLTC	CFD	CTSC
CEBPD	CLDN3	CDKN2A	CDKN3	CD3D	CSTB	CCN1	CLU	CLIC3	CTSD
CFD	CLDN4	CHI3L1	CENPA	CD3E	CYB5A	CD55	CNN3	CLU	CTSS
CLDN4	CNN3	COL1A2	CENPE	CD48	CYBA	CDKN1A	CTNNB1	COX6C	CXCL1
CLU	COL12A1	COL6A1	CENPF	CD52	CYC1	CEBPB	CTNND1	CSTB	CXCL17
COX6C	COX6C	COL6A2	CENPK	CD53	DBI	CEBPD	EFHD1	CTSD	CYBA
CPB1	CRIP1	COTL1	CENPM	CD69	DCXR	CFD	EGR1	CXCL14	DEFB1
CRIP1	CSRP1	CRYAB	CENPU	CD7	DSTN	CLDN3	ELF3	CXCL17	FDCSP
CST3	CSRP2	CSTA	CENPW	CD74	EEF1B2	CLDN4	EPCAM	DHRS2	GBP1
CTHRC1	CTNNB1	CXCL2	CIP2A	CD83	ELOC	CST3	ERBB2	DSCAM-AS1	GBP2
CXCL14	CTTN	DEFB1	CKAP2	CELF2	EMP2	CTD-3252C9-4	ESR1	DUSP1	HLA-A
DHRS2	CYSTM1	DEPP1	CKLF	COL1A2	FXYD3	CTSK	EVL	ERBB2	HLA-B
DSCAM-AS1	DDIT4	EFEMP1	CKS1B	CORO1A	GPX4	DHRS2	FOSB	FADS2	HLA-C
ELF3	DHRS2	FABP5	CKS2	CREM	GSTM3	DNAJB1	GATA3	FAM3D	HLA-DMA
ELP2	DLX5	FBXO32	CTHRC1	CST7	H2AJ	DUSP1	GRB7	FHL2	HLA-DPA1
ERBB4	DSC2	FDCSP	DEK	CTSL	H2AZ1	EDN1	H4C3	GDF15	HLA-DPB1
ESR1	EFHD1	FGFBP2	DLGAP5	CTSW	HINT1	EGR1	HES1	GLYATL2	HLA-DQA1
EVL	EFNA1	FN1	DTYMK	CXCR4	HMGB1	ELF3	HLA-B	GPX1	HLA-DQA2
FABP3	ELF5	GABRP	DUT	CYBB	HSPE1	ELOVL2	HNRNPH1	GSN	HLA-DQB1
FHL2	ENO1	GSTP1	ECT2	CYTIP	IDH2	ESR1	HSPA1A	GSTP1	HLA-DRA
FKBP5	FAM229B	HLA-A	FAM111A	DUSP2	JPT1	FHL2	HSPA1B	HDC	HLA-DRB1
FSIP1	FASN	HLA-B	FAM111B	EMP3	KDEL2	FOS	IGFBP5	HSPB1	HLA-DRB5
GJA1	GJA1	ID1	GGH	FCER1G	KRT10	FOSB	INTS6	IGFBP5	HLA-E
GSTM3	GRIK1-AS1	IFI27	GTSE1	FN1	KRT18	GATA3	ITGB1	ISG20	ID3
HES1	GSTP1	IGFBP3	H1-2	FYB1	KRT19	GDF15	ITGB6	ITM2A	IFI16
HSPB1	H2AJ	IGFBP5	H1-3	GIMAP7	KRT7	GRB7	ITM2B	KRT23	IFI27
IFI27	HILPDA	IGFBP7	H2AZ1	GMFG	KRT8	GSTM3	JUN	KRT7	IFI44L
IFI6	HNRNPH1	IL32	H2AZ2	GPR183	LGALS1	H1-2	KLF6	LGALS1	IFI6
IFITM1	HSPA5	KLK5	H2BC11	GPSM3	LGALS3	HES1	KRT7	LGALS3	IFIT1
IFITM2	IFI27	KLK7	H4C3	GZMA	LSM3	ICAM1	LDLRAD4	LY6E	IFIT2
IFITM3	IFITM3	KRT14	HELLS	GZMK	LSM4	ID2	LMNA	MARCKS	IFIT3
IGFBP4	IGKC	KRT15	HMGB1	HCST	LY6E	IER2	LRATD2	MFGE8	IFITM1

(Continued on next page)

Table 3. Continued

GE1	GE2	GE3	GE4	GE5	GE6	GE7	GE8	GE9	GE10
INPP4B	JPT1	KRT16	HMGB2	HLA-DPA1	MARCKSL1	IER3	MAGED2	MGP	IFITM2
ISG15	KCNC2	KRT17	HMGB3	HLA-DPB1	MIEN1	IFITM1	MAL2	MS4A7	IFITM3
JUNB	KRT15	KRT5	HMG2	HLA-DQA1	MIF	IGFBP4	MARCKS	MT-ATP8	IGFBP7
KCNE4	KRT23	KRT6A	HMMR	HLA-DRA	MPC2	IGFBP5	MT-ND4L	MTCO2P12	IL32
KCNJ3	KRT7	KRT6B	IQGAP3	HLA-DRB1	MRPL12	IRF1	MT2A	MUC5B	IRF1
KRT18	LAPTM4B	KRT81	KIF20B	IGSF6	MRPL51	JUN	MUC1	MUCL1	ISG15
KRT19	LDHB	LAMB3	KIF23	IL2RG	MRPS34	JUNB	MYH9	NDRG2	KRT15
LDLRAD4	LMO4	LCN2	KIF2C	IL32	MTDH	KLF4	NEAT1	NFKBIZ	KRT19
MAGED2	LTF	LTF	KNL1	IL7R	MUCL1	KLF6	NFIB	NPW	KRT5
MDK	MAFB	LY6D	KPNA2	ISG15	NDUFB9	KRT15	PERP	NR4A1	KRT7
MESP1	MAL2	MFAP5	LGALS1	ITGB2	NDUFC2	KRT18	PKM	NUDT8	LCN2
MGP	MAOB	MFGES	MAD2L1	KLRB1	NME1	LGALS3	PLAT	PALMD	LGALS1
MGST1	MFAP2	MGP	MKI67	LAPTM5	PAFAH1B3	MAFB	PMEPA1	PDZK1IP1	LGMN
MRPS30	MGST1	MIA	MT2A	LCK	PFND2	MAGED2	PSAP	PERP	LTF
MRPS30-DT	MRPL15	MMP7	MYBL2	LIMD2	PFN1	MGP	RAD21	PHGR1	LUM
MS4A7	MT1X	MT1X	MZT1	LSP1	PIP	NAMPT	RBP1	PIP	LY6D
MT-ATP8	MUCL1	MT2A	NEK2	LST1	POLR2K	NCOA7	RHOB	PLAT	LYZ
NOVA1	MYBPC1	MYL9	NUF2	LTB	PPDPF	NFKBIA	RUNX1	PRSS21	MAFB
PEG10	NME2	MYLK	NUSAP1	LY96	PSMA7	NFKBIZ	S100A10	PSCA	MARCKS
PHGR1	NUPR1	NDRG1	PBK	LYZ	PSMB3	NR4A1	SAT1	PTHLH	MGP
PI15	PCSK1N	NDUFA4L2	PCLAF	MEF2C	PSME2	NR4A2	SCARB2	PYDC1	MIA
PIP	PFN2	NFKBIA	PCNA	MNDA	RAN	PERP	SCD	RGS10	MMP7
PLAAT4	PHGDH	NNMT	PLK1	MS4A6A	RANBP1	PLAT	SDC1	RGS2	MRPS30-DT
PLAT	PRSS23	PDLIM4	PRC1	MSR1	RBIS	PMAIP1	SERHL2	RHCG	MX1
PRSS23	PSMB3	PLS3	PRR11	NKG7	REEP5	PRSS23	SH3BGRL3	RP11-53O19-2	NNMT
PSD3	PTHLH	POSTN	PTTG1	PTPRC	ROMO1	REL	SHISA2	S100A1	PI3
PVALB	PTPN1	PRNP	RACGAP1	RAC2	RPS26	RHOV	SLC38A2	S100A10	PIGR
RAMP1	RAMP1	PTN	RAD21	RGCC	S100A14	RND1	SLC39A6	S100A6	RAMP2
RBP1	RAMP3	RARRES1	RHEB	RGS1	S100A16	S100P	SLC40A1	S100A7	RARRES1
RHOBTB3	RBP1	RCAN1	RNASEH2A	RGS2	SEC61G	SAT1	SOX4	S100A8	RHCG
SCGB3A1	RSU1	RGS2	RPL39L	RNASE1	SELENOP	SLC39A6	SYTL2	S100A9	RNASE1
SCUBE2	S100A10	S100A2	RRM2	S100A4	SH3BGRL	SLC40A1	TACSTD2	S100P	RSAD2
SEMA3C	S100A6	S100A4	SMC4	S100A6	SLC9A3R1	SOCS3	TCAF1	SAA2	S100A8
SERPINA1	SCUBE2	S100A6	SPC25	SEPTIN6	SMIM22	SOX4	TCIM	SCGB1D2	S100A9
SH3BGRL	SFRP1	S100A8	STMN1	SLC2A3	SNRPB	SOX9	TFAP2B	SCGB2A1	S100P
SLC39A6	SH3BGRL	S100A9	TFDP1	SMAP2	SNRPG	STC2	TIMP1	SCGB2A2	SAA2
SLC40A1	SLC39A4	SAA1	TK1	SOCS1	SPINT2	TACSTD2	TM4SF1	SDC2	SCGB1D2
SNCG	SLC40A1	SAA2	TMEM106C	SPARC	SQLE	TCIM	TMC5	SERHL2	SCGB2A1
STC2	SOX4	SBSN	TMPO	SPP1	SRP9	TFF1	TMEM123	SERPINA1	SERPING1
TCEAL4	STC2	SERPING1	TOP2A	SRGN	STARD10	TIMP3	TPM1	SLC12A2	SLC39A6
TCIM	STOM	SFRP1	TPX2	STK4	TCEAL4	TM4SF1	TRPS1	SLC18A2	SOD2
TFF1	TCIM	SGK1	TROAP	TMSB4X	TMCO1	TNFRSF12A	TSC22D1	SLPI	SPATS2L
TFF3	TFF3	SLC25A37	TTK	TNFAIP3	TMEM14B	TSC22D3	TSPYL1	SYNM	TCIM
TIMP1	TMSB4X	SLPI	TUBA1B	TRAC	TPI1	TUBA1A	TUBA1A	TACSTD2	TFF1
TMC5	TTYH1	SPARC	TUBA1C	TRBC1	TPM1	VASN	VEGFA	TFF1	TFF3
TPM1	TUBA1A	SPARCL1	TUBB	TRBC2	TSPAN13	VEGFA	WSB1	TFF3	TMEM45A
TPRG1	UBE2V2	TAGLN	TUBB4B	TREM2	TUBA1B	VTCN1	XIST	TM4SF1	TNFAIP6
VSTM2A	VIM	THBS1	TYMS	TYROBP	TUBB	XBP1	YBX1	TMC5	TNFSF10

(Continued on next page)

Table 3. Continued

GE1	GE2	GE3	GE4	GE5	GE6	GE7	GE8	GE9	GE10
VTCN1	YBX1	TPM2	UBE2C	VIM	UQCRQ	ZFAND2A	YBX3	TSC22D3	TXNIP
WFDC2	YBX3	TSHZ2	UBE2S	WIPF1	XBP1	ZFP36	ZFP36L1	TSPAN1	WFDC2
XBP1	YWHAH	VIM	UBE2T	ZEB2	YBX1	ZFP36L1	ZFP36L2	TXNIP	XBP1
ZFP36L1	YWHAZ	ZFP36L2	ZWINT	ZNF331	ZNF706	ZFP36L2	ZNF292	XBP1	ZFP36

non-HER2+ tumors did not show significant association with nodal status ($p = 0.25$) (Figures 2G, S7A, and S7B). However, tumors with an increased proportion of *TACSTD2*-expressing cells were significantly associated with higher nodal status ($p = 0.015$) (Figure 2H). When performing this analysis separately in each cohort, the combined result by Fisher's combined probability was not statistically significant, though it trended toward significance ($X = 11.227$, $p = 0.08$) (Figure S7C). This again highlights the value of our data integration approach, which creates a more statistically powered dataset and enables evaluation of correlations with clinical features over traditional meta-analysis methods.

Our study joins several reports noting the heterogeneous expression of single genes within single tumors.^{48–51} Recognizing that intratumoral heterogeneity occurs beyond single genes, we next characterized the ITTH of cancer epithelial cells in primary breast tumors. To do so, we applied a well-characterized SC50 molecular subtype classifier¹³ that scores the four molecular subtypes (luminal A, luminal B, Her2, and basal) to cancer epithelial cells in the integrated dataset. We found that each patient tumor expressed differing proportions of cells from each molecular subtype with a varied degree of concordance with the clinical subtype diagnosis (Figure 2I). This finding prompted us to explore how cancer epithelial cell ITTH may be influenced by features beyond molecular subtype. We quantified the degree of heterogeneity across all cancer epithelial cells in a patient tumor using ROGUE analysis (Figure 2I).⁵² The ROGUE score for each individual tumor sample also reflected molecular subtype heterogeneity to some degree; however, we noticed discordance in 33.3% of samples, which demonstrated homogeneity based on molecular subtype but high heterogeneity based on ROGUE score (Figure 2J; STAR Methods). This suggests that other factors beyond molecular subtype-associated genes drive the observed heterogeneity and underscores a need for different approaches to study cancer epithelial cell ITTH at higher resolution than that of existing subtype classifiers.

Cancer epithelial cell heterogeneity can be defined by 10 unifying groups of gene signatures

To develop a high-resolution classifier of heterogeneous cancer epithelial cells, we first performed unsupervised clustering on all cancer epithelial cells in the integrated dataset to generate signatures of upregulated genes that capture distinct molecular features of cancer epithelial cell clusters. Next, supervised classification was performed based on expression of 12 clinical therapeutic targets (*ESR1*, *ERBB2*, *ERBB3*, *PIK3CA*, *NTRK1/NTRK2/NTRK3*, *CD274*, *EGFR*, *FGFR1/FGFR2/FGFR3/FGFR4*, *TACSTD2*, *CDK4/CDK6*, *AR*, and *NECTIN2*) to ensure that clinically relevant associations were captured by upregulated gene

signatures (STAR Methods). The motivation for including therapeutic targets was to create classifications grounded in relevant clinical approaches. We additionally supervised classification of all cancer epithelial cells based on molecular subtype to generate upregulated gene signatures that reflect subtype features. Consensus clustering of all generated gene signatures identified 10 unifying groups, which we defined as “gene elements” (GEs) (Figures S8A and S8B). We defined each GE by the top 100 genes that occurred most frequently across gene signatures assigned to the group (Table 3; STAR Methods). We scored each cancer epithelial cell by the individual 10 GEs and assigned GE-based cell labels (Figure 3A; STAR Methods).

When assessing for molecular subtypes, GE3-labeled cells were predominantly assigned to the basal subtype, while the majority of GE9-labeled cells were assigned to the Her2 subtype (Figure 3B). Cells labeled by GE1 and GE7 were almost exclusively assigned as luminal A and luminal B. In contrast, GE5- and GE10-labeled cells were assigned to all molecular subtypes. Next, we used gene set enrichment analysis (Figure 3C) to identify functional annotations for each GE. This analysis identified shared and distinct functional features for all GEs. GE4 was uniquely enriched for cell cycle and proliferation hallmarks (*MKI67*, *PCNA*, and *CDK1*). GE2 and GE3 contained hallmark genes of EMT (*VIM* and *ACTA2*). GE1, GE6, GE7, and GE9 contained genes associated with estrogen response (*ESR1*, *AREG*, and *TFE3*). GE5 and GE10 were enriched for hallmarks of allograft rejection (*HLA-DRA* and *HLA-DRB1*) and complement (*C1QA/B/C* and *C1R*).

To assess how GE-based cell labels allow us to characterize cancer epithelial cell heterogeneity within a tumor sample, we applied our GEs to the integrated dataset to deconstruct each individual patient tumor into the 10 GEs (Figure S8C). Notably, GE-based heterogeneity was not constrained by clinical or molecular subtype. This again confirms that significant cancer epithelial cell ITTH exists even within cells from a tumor labeled by a single clinical or molecular subtype. Overall, we generated 10 GEs to characterize cancer epithelial cell ITTH and deconstruct a heterogeneous tumor into its diverse cellular phenotypes.

GEs predict individual patient predominant immune response

To examine how cancer epithelial cell ITTH influences immune interactions in the TME, we generated a decoder matrix of predicted GE-immune interaction strength. GE-immune interaction strength is determined based on the scaled number of predicted receptor-ligand pairings between GEs and immune cells (Figures 3D and S8D; STAR Methods).

To experimentally validate the decoder matrix, we tested these predictions with human breast cancer cell lines. In the




Figure 3. Cancer epithelial cell heterogeneity can be defined by 10 GEs that influence immune cell interactions

(A) Heatmap of Z-scored signature scores of the 10 identified gene elements (GEs) representing all cancer epithelial cells, ordered based on the maximum Z-scored GE signature score. Annotations represent dataset origin, clinical subtype, PAM50 subtype, and SC50 subtype. The “sample” annotation was included to demonstrate that no individual patient sample contributed heavily to a particular GE.

(B) Percentage of cancer epithelial cells assigned to each GE by molecular subtype.

(C) Gene set enrichment using ClusterProfiler of the differentially expressed genes by GE. Significantly enriched gene sets from the MSigDB Hallmark collection are shown (Benjamini-Hochberg-adjusted $p < 0.05$).

(D) Heatmap of the scaled number of curated predicted receptor-ligand pairs between cancer epithelial cells by GE and interacting immune and stromal cells.

(E) Scatterplots showing Spearman correlations of expression of NK cell related GE1 and GE6 with sensitivity to NK cell killing (Benjamini-Hochberg-adjusted $p < 0.05$).

(F) Circos plots showing curated receptor-ligand pairs between cancer epithelial cells that highly express NK cell-related GE1 and GE6 with NK cells. NK cell activating receptor-ligand pairs are colored blue; NK cell inactivating receptor-ligand pairs are colored red.

See also [Figure S8](#).

decoder matrix, cancer epithelial cells labeled by GE1 and GE6 were predicted to highly interact with NK cells (GE1 and GE6 have the highest scaled number of curated receptor-ligand pairings). We applied the GEs to human breast cancer cell lines from the Cancer Cell Line Encyclopedia to quantify GE expression across cell lines ([Figure S8E](#)). Given that GE1 and GE6 have the greatest predicted interaction strength with NK cells ([Fig-](#)

[ure 3D](#)), we hypothesized that expression of these GEs will have a significant influence on NK cell function (i.e., sensitivity or resistance of cancer cell lines to NK cell killing). To test this, we selected breast cancer cell lines with differing expression of GE1 and GE6. BT-474 had increased expression of GE1 and GE6, while MDA-MB-436 had decreased expression of GE1 and GE6. Using these selected cell lines, we assessed the




Figure 4. GE-immune interactions predict response to anti-PD-1 therapy

(A) Heatmap of Pearson correlations between expression of each of the 10 GEs and the presence of CD8⁺ T cells for 6 spatial transcriptomics samples across spots containing CD8⁺ T cells (n.s., Benjamini-Hochberg-adjusted $p > 0.05$).

(B) For a representative TNBC sample, pathological annotation of morphological regions into distinct categories. UCell signature scores of CD8⁺ T cells are overlaid onto spatial tumor sample spots (red). A UCell signature score of GE5 (a CD8⁺ T cell activating GE) is overlaid onto tumor sample spots (red). A co-localization score for *ITGB2_ITGAL*, *LTB_TNFRSF1A*, and *ALOX5AP_ALOX5* (predicted receptor-ligand pairs for GE5 and CD8⁺ T cells) is overlaid onto tumor sample spots (red).

(legend continued on next page)

relationship between GE1 and GE6 expression and sensitivity to NK cell killing. We co-cultured BT-474 (GE1 and GE6 high) and MDA-MB-436 (GE1 and GE6 low) with NK-92, a human NK cell line. As hypothesized, GE1 and GE6 expression had a statistically significant impact on NK cell function. NK cell cytotoxicity against BT-474 at 24 h was significantly reduced ($p < 0.0001$) compared with NK cell cytotoxicity against MDA-MB-436 (Figure S8F). This finding suggests that GE1 and GE6 confer resistance to NK cell cytotoxicity. Next, to expand on these experimental findings, we used a study by Sheffer et al.,⁵³ which reports experimental sensitivity or resistance of 26 breast cancer cell lines to NK cell cytotoxicity (STAR Methods).^{53,54} Increased GE1 and GE6 expression was significantly correlated with increased resistance to NK cell killing ($R = -0.54$, $p < 0.05$ for GE1; $R = -0.54$, $p < 0.05$ for GE6) (Figure 3E), consistent with the decoder matrix and our experimental findings. Other GEs with fewer predicted NK cell interactions in the decoder matrix did not have statistically meaningful correlations with sensitivity to NK cells (Figure S8G). To investigate interactions that contribute to these phenotypes, we assessed predicted receptor-ligand pairs between cells that highly express GE and NK cells (Figure 3F). We observed that GE1- and GE6-labeled cells were predicted to have receptor-ligand pairs that have been characterized as inactivators of NK cell activity (e.g., *NECTIN2_TIGIT*, *THBS1_CD47*, and *CD320_TGFRB2*). These functional studies validate two of the predictions made by the decoder matrix by showing that GE1 and GE6 are predictive of significant resistance to NK cell killing for breast cancer cell lines.

Overall, this decoder matrix provides a blueprint for quantifying the degree of interactions between each GE and different immune cell types. Moreover, this decoder matrix curates key activating and inhibitory receptors that can be used to infer how GE-immune interactions affect immune cell behavior.

Spatial mapping of GEs reflects predicted immune interactions

To validate the predicted interactions curated by the decoder matrix, we used a spatial transcriptomics dataset containing published data from 10× Genomics and from Wu et al.¹³ We first deconvoluted the underlying composition of cell types through integration of the spatial transcriptome data with the integrated dataset (STAR Methods). Because T cell infiltration was relatively high across spatial transcriptomics samples (Figure S9A), we chose to explore T cell interactions using this dataset. To do so, we applied the 10 GEs to each sample in the dataset. Using the decoder matrix, we inferred which GE-labeled cells interact with T cells and which ones do not. Thus, we hypothesized that these GE-labeled cells and CD8⁺ T cells would be spatially orga-

nized in breast tumors. To test this, we examined the co-expression of the GEs and the presence of neighboring CD8⁺ T cells. Notably, GE5 expression demonstrated positive correlations with CD8⁺ T cells in all samples (mean $R = 0.33$, all $p < 0.0001$) (Figure 4A). In one representative image, we determined the co-localization of CD8⁺ T cells with GE5 expression (Figure 4B). For areas with high presence of CD8⁺ T cells, we observed increased colocalization of select curated receptor-ligand pairs (*ITGB2_ITGAL*, *LTB_TNFRSF1A*, and *ALOX5AP_ALOX5*) (Figure 4B). As expected, GEs with limited predicted interactions did not consistently co-localize with CD8⁺ T cells (Figure S9B).

InteractPrint: A weighted score to predict the predominant tumor-interacting immune cell for an individual patient tumor

We then hypothesized that the GE-immune interaction decoder matrix could be applied to individual tumor tissues. To account for how cancer epithelial cell ITTH within a tumor influences immune cell interactions, we developed InteractPrint. InteractPrint reflects interactions between the predominant tumor-responsive immune cells from the decoder matrix and cancer cells that highly express each GE, weighted by the GE composition of an individual patient tumor. This approach permits real-world application of InteractPrint since it accounts for heterogeneity of GEs within a tumor.

InteractPrint predicts anti-PD-1 therapeutic response

We then sought to use InteractPrint to characterize the predominant immune response within patients for therapeutically targeted immune cells. Because current immune checkpoint inhibitors (ICI) target CD8⁺ T cell-driven cancers, we developed T cell InteractPrint to predict who might respond to ICI. For the comparator, average PD-L1 expression on cancer epithelial cells was selected, as PD-L1 remains the main biomarker used clinically to determine who should receive ICI for many solid tumors, including patients with recurrent unresectable or metastatic triple-negative breast cancer (TNBC).^{55,56}

We applied our approach to a separate scRNA-seq dataset published by Bassez et al.,⁵⁷ which contains tumor biopsies from breast cancer patients pre and post anti-PD-1 therapy (Figures S8C and S8D). Deconstruction of each individual patient tumor into the 10 GEs revealed considerable cancer epithelial cell ITTH prior to anti-PD-1 treatment (Figure 4C), similar to what was observed in the integrated dataset (Figure S8C). To assess the capacity of the T cell InteractPrint to predict responders to anti-PD-1 therapy, we derived receiver operating characteristic (ROC) curves in this dataset (Figure 4D). Across clinical subtypes of breast cancer, the T cell InteractPrint demonstrated an area

(C) Heatmap of average expression of each of the 10 GEs across cancer epithelial cells in each sample from Bassez et al.⁵⁷ T cell InteractPrint is shown below. (D) Boxplot showing T cell InteractPrint prediction of response to anti-PD-1 therapy across all clinical subtypes in Bassez et al.⁵⁷ (R, responder; NR, non-responder; $p < 0.05$). Also shown is the AUC of ROC comparing the performance of T cell InteractPrint (AUC = 81.87) and of PD-L1 expression (AUC = 49.71) in Bassez et al.⁵⁷ samples (bootstrap test with $n = 10,000$, $p < 0.05$).

(E) Heatmap of average expression of each of the 10 GEs across cancer epithelial cells in each sample from the I-SPY2 trial. T cell InteractPrint is shown below. (F) Boxplot showing T cell InteractPrint prediction of response to anti-PD-1 therapy across all clinical subtypes in I-SPY2 trial samples (two-sided Wilcoxon test $p < 0.0001$). Also shown is the AUC of ROC comparing the performance of T cell InteractPrint (AUC = 83.02) and of PD-L1 expression (AUC = 72.33) in the I-SPY2 trial (bootstrap test with $n = 10,000$, $p < 0.05$).

(G) Schematic of T cell InteractPrint to predict patient response to anti-PD-1 therapy. See also Figure S9.

under the curve (AUC) of 81.87% ($p = 0.0061$) in predicting response to anti-PD-1 therapy, inferred from T cell clonotype expansion.⁵³ This was a significant improvement ($p = 0.019$) over average PD-L1 expression on cancer epithelial cells, the current clinical biomarker to predict patients who will respond to anti-PD-1 therapy in breast cancer, which had an AUC of 49.71% ($p > 0.05$).

Next, we applied our predictor to a separate validation dataset containing results from the I-SPY2 trial. I-SPY2 is an ongoing, multicenter, open-label, adaptively randomized phase 2 trial of neoadjuvant chemotherapy for early-stage breast cancer at high risk of recurrence.⁵⁷ In this trial, patients with breast cancer received anti-PD-1 therapy (the same as patients from Bassez et al.⁵⁷) combined with paclitaxel. We applied the 10 GEs to microarray data from pre-treatment tumor samples from the I-SPY2 trial and observed levels of heterogeneity that were comparable with those described in the scRNA-seq datasets (Figure 4E). In the I-SPY2 trial dataset, T cell InteractPrint (AUC = 83.02%, $p = 8.1 \times 10^{-7}$) demonstrated significant improvement ($p = 0.034$) over average PD-L1 expression on cancer epithelial cells (AUC = 72.33%, $p = 0.001$) in predicting response to anti-PD-1 therapy (Figure 4F).

Across two trials, T cell InteractPrint demonstrated significant improvement over PD-L1 at predicting response to anti-PD-1 therapy. This highlights the ability of T cell InteractPrint to decode how cancer epithelial cell ITTH impacts CD8⁺ T cell response for each individual patient.

DISCUSSION

In this study, we present an atlas resource that integrates scRNA-seq data of 236,363 cells that represent the breast TME. This resource enables high-resolution characterization of rare immune cell and cancer epithelial cell heterogeneity and demonstrates how heterogeneity influences immune cell interactions that have not been evaluated previously.

First, we leveraged the statistical power of this integrated dataset to demonstrate how NK cells, a population of rare immune cells that have not been classified in the breast TME, can be studied further. We identified six subsets of NK cells, which consist of activated and cytotoxic, exhausted, and rNK cells. Identification of rNK cells in most but not all samples (i.e., 72% of samples) provides a subtype-independent approach to identify patients who may benefit from rNK cell-directed therapies. We also performed receptor-ligand analysis on rNK cells and tumor cells to identify potential interactions that could lead to this phenotype (Figure 1H). Interestingly, *KLRG1* is among the identified interactions between HER2+ cancer epithelial cells and rNK cells. *KLRG1* was previously validated as a potential regulator of rNK cell function.²⁰ Ongoing and future experimental work by is needed to determine mechanisms that drive this distinct and functional rNK cell phenotype. Our findings add to the growing body of literature on distinct NK cell subsets and phenotypes. In particular, the gene expression profile of the cytotoxic NK-2 subset aligns with CD56^{dim} subsets identified previously in bone marrow by Crinier et al.²⁵ and Yang et al.,²⁷ in peripheral blood by Smith et al.,²⁶ and in human melanoma metastases by de Andrade et al.²⁸ The NK-0 subset closely resembles previously described “memory-like” NK cells

derived from bone marrow by Crinier et al.²⁵ and have been described after viral or tumor exposure. Our description of NK-4 aligns with prior observations of “inflamed” interferon (IFN)-responding NK cells in the bone marrow by Yang et al.²⁷ and in peripheral blood by Smith et al.²⁶ NK-3 demonstrated features consistent with prior studies of tissue-resident NK cells derived from bone marrow by Yang et al.²⁷ and from melanoma metastases by de Andrade et al.²⁸ The unique transcriptional profile of the NK-5 subset has been described previously as exhausted.^{34,35} Last, expression profiles (e.g., upregulated *NR4A* family, *DUSP1*, *FOS*, and *JUN*) similar to the rNK-1 subset have been described in peripheral blood by Smith et al.,²⁶ in bone marrow by Yang et al.,²⁷ and in human head and neck cancers by Moreno-Nieves et al.,²⁹ as well as in our prior studies on metastasis-promoting NK cells derived from *ex vivo* and mouse models.²⁰ Additionally, our present study is the first to identify six subsets of NK cells in human primary breast tumors, which can now be quantified and measured in response to prospective therapeutics.

Through this analysis, we observed that NK cell heterogeneity is associated with breast cancer clinical subtypes. These clinical subtypes are well known to harbor substantial heterogeneity.^{23,24,40} This led us to use this resource to further understand clinically relevant heterogeneity within the breast TME and cancer epithelium at resolutions higher than studied previously. At the single-cell resolution, we quantified the heterogeneity of single-gene expression (i.e., *ERBB2* and *TACSTD2*) across tumors and found that the majority of samples across all breast cancer subtypes expressed *ERBB2* and *TACSTD2*. These findings prompt further functional investigation of what degree of transcriptomic expression correlates with clinical efficacy of anti-HER2 and anti-TROP2 antibody-drug conjugates. The new class of antibody-drug conjugates targeting these proteins has recently demonstrated efficacy across breast cancer subtypes. For HER2/*ERBB2*, high concordance between proteomic HER2 status and *ERBB2* mRNA expression has been reported in the literature,^{58–63} and we corroborate these findings in the integrated dataset (Figure S6D). Similarly, for TROP2/*TACSTD2*, concordance between proteomic TROP2 and *TACSTD2* mRNA expression has been reported in various solid tumors, including breast.^{54–69} Further, examining genes that are positively correlated with *ERBB2* and *TACSTD2* uncovers other potential clinical targets that can synergize with current anti-HER2 and anti-TROP2 therapies and provides a rationale for novel combination approaches. Then, we characterized cancer epithelial cell heterogeneity by using unsupervised clustering and supervised classification based on breast cancer molecular subtypes and clinical therapeutic target gene expression. While discrepancies between clinical and molecular subtyping have been well documented, we provide an approach to defining cancer epithelial cell heterogeneity at the single-cell level by using 10 GEs. This approach enables high-resolution characterization of cancer epithelial cell ITTH and deconstruction of a heterogeneous tumor into its diverse epithelial phenotypes.

To further demonstrate how this resource facilitates analysis of the breast TME, we then use information from the 10 GEs to identify how cancer epithelial cell heterogeneity influences interactions with immune populations. Current ICI biomarker

approaches mainly focus on the expression of single targets, resulting in an incomplete characterization of the TME complexity. Our approach for T cell InteractPrint score calculates cancer epithelial cell heterogeneity within a tumor sample and the number of predicted interactions between heterogeneous cancer epithelial cells and CD8⁺ T cells (Figure 4G). This captures how heterogeneous expression of GEs shifts the predicted strength of T cell interactions for an individual patient's tumor. Across two trials and all subtypes of breast cancer, T cell InteractPrint predicted response to T cell immune checkpoint inhibition. This finding is significant because anti-PD-1 therapy is not effective in HR+ disease⁷⁰ and has limited efficacy in TNBC disease⁷¹ compared with the response seen in other solid tumors.^{72–75} The development of InteractPrint from this resource serves as another example of how this resource can be used to uncover biology that, once validated, could inform response to ICI in breast cancer.

The breast TME is a complex ecosystem that encompasses diverse cell phenotypes, heterogeneous interactions among cells, and varied expression of clinically targetable features. The development of this resource and examples of its utility uncovered information about NK cells and how heterogeneous cancer epithelial cells and their predicted immune interactions can predict immune checkpoint therapy responses. Future use of this resource is likely to yield additional impactful findings.

Limitations of the study

A limitation of our study is that we compared InteractPrint with PD-L1 by transcriptomic expression in early-stage breast cancer trials. PD-L1 expression by IHC is approved in the setting of recurrent unresectable or metastatic TNBC disease for selection of patients to receive ICI.⁷⁶ However, PD-L1 expression has been associated with increased response rates in neoadjuvant trials,^{77–81} and concordance between PD-L1 mRNA and proteomic expression has been shown.^{82–85} While this provides the rationale behind our selection of PD-L1 transcriptomic expression as the comparator for T cell InteractPrint, a discussion of the limitations of this comparator is necessary. First, assessment of PD-L1 expression based on mRNA levels rather than proteomic expression is not widely used in the clinic. Second, across the neoadjuvant trials, differences in study design, patient enrollment, and subgroup analyses make it difficult to reconcile mixed findings around the role of PD-L1 as a biomarker in early-stage breast cancer. Last, evaluation of other exploratory biomarkers is ongoing.^{86–89} There is still an outstanding need for improved patient selection to maximize efficacy and minimize exposure to adverse events associated with ICIs. These limitations define a need for future prospective studies to compare T cell InteractPrint and PD-L1 gene and protein expression, along with other exploratory biomarkers, to predict response to ICI.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCES AVAILABILITY**
 - Lead contact

- Materials availability
- Data and code availability

- **EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS**

- NK-92
- BT-474
- MDA-MB-436
- K-562

- **METHOD DETAILS**

- Processing of single-cell RNA-seq datasets
- Integration of primary breast tumor datasets
- Cell type annotation and clustering
- Identification of natural killer cell subsets
- Survival analysis
- Identification of epithelial cell clusters
- Molecular subtype of samples using SCSsubtype
- Cancer epithelial cell heterogeneity analysis
- Receptor-ligand pairing analysis
- Breast cancer cell line exploration
- Spatial transcriptomics analysis
- Development of InteractPrint
- Validation of InteractPrint

- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.xcrm.2024.101511>.

ACKNOWLEDGMENTS

We thank Drs. Carlos Arteaga, Suzanne Conzen, and John Minna for reading our manuscript and providing helpful feedback. This study was supported by funding provided by METAvivor, Susan G. Komen (CCR231010879), the NIH (1K08CA270188-01A1), the Peter Bradley Carlson Trust, the Theresa's Research Foundation, and the NCI/UTSW Simmons Cancer Center (P30 CA142543). Special thanks to all members of the Chan Lab.

AUTHOR CONTRIBUTIONS

Conceptualization, L.X., K.S., S.-P.H., J.M., C.H., and I.S.C.; methodology, L.X., K.S., S.-P.H., H.K., K.C., L.X., and I.S.C.; investigation, L.X., K.S., S.-P.H., H.R., K.M.-A., I.T., K.C., and I.S.C.; visualization, L.X., K.S., S.-P.H., and I.S.C.; writing – original draft, L.X., K.S., S.M.R., E.T.R.T., J.M., C.H., L.X., and I.S.C.; writing – revision, L.X., K.S., H.L.M., S.M.R., E.T.R.T., J.M., C.H., L.X., and I.S.C.; funding acquisition, I.S.C.; supervision, I.S.C.

DECLARATION OF INTERESTS

I.S.C., L.X., and K.S. are co-inventors on a pending patent application for a method to determine a predominant immune signal in a breast tumor microenvironment.

Received: March 9, 2023

Revised: February 20, 2024

Accepted: March 20, 2024

Published: April 12, 2024

REFERENCES

1. Siegel, R.L., Miller, K.D., Fuchs, H.E., and Jemal, A. (2022). Cancer statistics, 2022. *CA A Cancer J. Clin.* 72, 7–33. <https://doi.org/10.3322/caac.21708>.

2. Hunker, A.B., Sudhan, D.R., and Arteaga, C.L. (2020). Overcoming Endocrine Resistance in Breast Cancer. *Cancer Cell* 37, 496–513. <https://doi.org/10.1016/j.ccell.2020.03.009>.
3. Al-Hajji, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). Prospective identification of tumorigenic breast cancer cells. *Proc. Natl. Acad. Sci. USA* 100, 3983–3988. <https://doi.org/10.1073/pnas.0530291100>.
4. Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis.* 5, 77–106. <https://doi.org/10.1016/j.gendis.2018.05.001>.
5. Place, A.E., Jin Huh, S., and Polyak, K. (2011). The microenvironment in breast cancer progression: biology and implications for treatment. *Breast Cancer Res.* 13, 227. <https://doi.org/10.1186/bcr2912>.
6. Polyak, K. (2007). Breast cancer: origins and evolution. *J. Clin. Invest.* 117, 3155–3163. <https://doi.org/10.1172/JCI33295>.
7. Azizi, E., Carr, A.J., Plitas, G., Cornish, A.E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018). Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. *Cell* 174, 1293–1308.e36. <https://doi.org/10.1016/j.cell.2018.05.060>.
8. Karaayvaz, M., Cristea, S., Gillespie, S.M., Patel, A.P., Mylvaganam, R., Luo, C.C., Specht, M.C., Bernstein, B.E., Michor, F., and Ellisen, L.W. (2018). Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. *Nat. Commun.* 9, 3588. <https://doi.org/10.1038/s41467-018-06052-0>.
9. Pal, B., Chen, Y., Vaillant, F., Capaldo, B.D., Joyce, R., Song, X., Bryant, V.L., Penington, J.S., Di Stefano, L., Tubau Ribera, N., et al. (2021). A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. *EMBO J.* 40, e107333. <https://doi.org/10.15252/embj.2020107333>.
10. Savas, P., and Loi, S. (2020). Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer. *Cancer Cell* 37, 623–624. <https://doi.org/10.1016/j.ccell.2020.04.007>.
11. Qian, J., Olbrecht, S., Boeckx, B., Vos, H., Laoui, D., Etilioglu, E., Wauters, E., Pomella, V., Verbandt, S., Busschaert, P., et al. (2020). A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. *Cell Res.* 30, 745–762. <https://doi.org/10.1038/s41422-020-0355-0>.
12. Wu, S.Z., Roden, D.L., Wang, C., Holliday, H., Harvey, K., Cazet, A.S., Murphy, K.J., Pereira, B., Al-Eryani, G., Bartonicek, N., et al. (2020). Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. *EMBO J.* 39, e104063. <https://doi.org/10.15252/embj.2019104063>.
13. Wu, S.Z., Al-Eryani, G., Roden, D.L., Junankar, S., Harvey, K., Andersson, A., Thennavan, A., Wang, C., Torpy, J.R., Bartonicek, N., et al. (2021). A single-cell and spatially resolved atlas of human breast cancers. *Nat. Genet.* 53, 1334–1347. <https://doi.org/10.1038/s41588-021-00911-1>.
14. Xu, K., Wang, R., Xie, H., Hu, L., Wang, C., Xu, J., Zhu, C., Liu, Y., Gao, F., Li, X., et al. (2021). Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis. *Oncogenesis* 10, 66. <https://doi.org/10.1038/s41389-021-00355-6>.
15. Verma, C., Kaewkangsan, V., Eremin, J.M., Cowley, G.P., Ilyas, M., El-Sheemy, M.A., and Eremin, O. (2015). Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. *J. Transl. Med.* 13, 180. <https://doi.org/10.1186/s12967-015-0535-8>.
16. Bouzidi, L., Triki, H., Charfi, S., Kridis, W.B., Derbel, M., Ayadi, L., Sellami-Boudawara, T., and Cherif, B. (2021). Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues. *Clin. Breast Cancer* 21, e738–e747. <https://doi.org/10.1016/j.clbc.2021.02.003>.
17. Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013). CD4+ follicular helper T cell infiltration predicts breast cancer survival. *J. Clin. Invest.* 123, 2873–2892. <https://doi.org/10.1172/JCI67428>.
18. Ruffell, B., Au, A., Rugo, H.S., Esserman, L.J., Hwang, E.S., and Coussens, L.M. (2012). Leukocyte composition of human breast cancer. *Proc. Natl. Acad. Sci. USA* 109, 2796–2801. <https://doi.org/10.1073/pnas.1104303108>.
19. Rezaeifard, S., Talei, A., Shariat, M., and Erfani, N. (2021). Tumor infiltrating NK cell (TINK) subsets and functional molecules in patients with breast cancer. *Mol. Immunol.* 136, 161–167. <https://doi.org/10.1016/j.molimm.2021.03.003>.
20. Chan, I.S., Knútsdóttir, H., Ramakrishnan, G., Padmanaban, V., Warriar, M., Ramirez, J.C., Dunworth, M., Zhang, H., Jaffee, E.M., Bader, J.S., and Ewald, A.J. (2020). Cancer cells educate natural killer cells to a metastasis-promoting cell state. *J. Cell Biol.* 219, e202001134. <https://doi.org/10.1083/jcb.202001134>.
21. Chan, I.S., and Ewald, A.J. (2022). The changing role of natural killer cells in cancer metastasis. *J. Clin. Invest.* 132, e143762. <https://doi.org/10.1172/jci143762>.
22. Melaiu, O., Lucarini, V., Cifaldi, L., and Fruci, D. (2019). Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors. *Front. Immunol.* 10, 3038. <https://doi.org/10.3389/fimmu.2019.03038>.
23. Polyak, K. (2011). Heterogeneity in breast cancer. *J. Clin. Invest.* 121, 3786–3788. <https://doi.org/10.1172/jci60534>.
24. Turashvili, G., and Brogi, E. (2017). Tumor Heterogeneity in Breast Cancer. *Front. Med.* 4, 227. <https://doi.org/10.3389/fmed.2017.00227>.
25. Crinier, A., Dumas, P.-Y., Escalière, B., Piperoglou, C., Gil, L., Villacreces, A., Vély, F., Ivanovic, Z., Milpied, P., Narni-Mancinelli, É., and Vivier, É. (2021). Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia. *Cell. Mol. Immunol.* 18, 1290–1304. <https://doi.org/10.1038/s41423-020-00574-8>.
26. Smith, S.L., Kennedy, P.R., Stacey, K.B., Worboys, J.D., Yarwood, A., Seo, S., Solloa, E.H., Mistretta, B., Chatterjee, S.S., Gunaratne, P., et al. (2020). Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing. *Blood Adv.* 4, 1388–1406. <https://doi.org/10.1182/bloodadvances.2019000699>.
27. Yang, C., Siebert, J.R., Burns, R., Gerbec, Z.J., Bonacci, B., Rymaszewski, A., Rau, M., Riese, M.J., Rao, S., Carlson, K.-S., et al. (2019). Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. *Nat. Commun.* 10, 3931. <https://doi.org/10.1038/s41467-019-11947-7>.
28. de Andrade, L.F., Lu, Y., Luoma, A., Ito, Y., Pan, D., Pyrdol, J.W., Yoon, C.H., Yuan, G.-C., and Wucherpfennig, K.W. (2019). Discovery of specialized NK cell populations infiltrating human melanoma metastases. *JCI Insight* 4, e133103. <https://doi.org/10.1172/jci.insight.133103>.
29. Moreno-Nieves, U.Y., Tay, J.K., Saumyaa, S., Horowitz, N.B., Shin, J.H., Mohammad, I.A., Luca, B., Mundy, D.C., Gulati, G.S., Bedi, N., et al. (2021). Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment. *Proc. Natl. Acad. Sci. USA* 118, e2101169118. <https://doi.org/10.1073/pnas.2101169118>.
30. Cheon, H., Borden, E.C., and Stark, G.R. (2014). Interferons and their stimulated genes in the tumor microenvironment. *Semin. Oncol.* 41, 156–173. <https://doi.org/10.1053/j.seminoncol.2014.02.002>.
31. Dogra, P., Rancan, C., Ma, W., Toth, M., Senda, T., Carpenter, D.J., Kubota, M., Matsumoto, R., Thapa, P., Szabo, P.A., et al. (2020). Tissue Determinants of Human NK Cell Development, Function, and Residence. *Cell* 180, 749–763.e13. <https://doi.org/10.1016/j.cell.2020.01.022>.

32. Chen, J., López-Moyado, I.F., Seo, H., Lio, C.-W.J., Hempleman, L.J., Sekiya, T., Yoshimura, A., Scott-Browne, J.P., and Rao, A. (2019). NR4A transcription factors limit CAR T cell function in solid tumours. *Nature* 567, 530–534. <https://doi.org/10.1038/s41586-019-0985-x>.
33. Zhou, F., Drabsch, Y., Dekker, T.J.A., De Vinuesa, A.G., Li, Y., Hawinkels, L.J.A.C., Sheppard, K.-A., Goumans, M.-J., Luwor, R.B., De Vries, C.J., et al. (2014). Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF- β signalling. *Nat. Commun.* 5, 3388. <https://doi.org/10.1038/ncomms4388>.
34. Chan, C.J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M.T., Town, L., Ritchie, D.S., Colonna, M., Andrews, D.M., and Smyth, M.J. (2014). The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. *Nat. Immunol.* 15, 431–438. <https://doi.org/10.1038/ni.2850>.
35. Braud, V.M., Allan, D.S., O’Callaghan, C.A., Söderström, K., D’Andrea, A., Ogg, G.S., Lazetic, S., Young, N.T., Bell, J.I., Phillips, J.H., et al. (1998). HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. *Nature* 391, 795–799. <https://doi.org/10.1038/35869>.
36. Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N.T., Prat, A., Chae, Y.S., et al. (2022). Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. *N. Engl. J. Med.* 387, 9–20. <https://doi.org/10.1056/nejmoa2203690>.
37. Rugo, H.S., Bardia, A., Marmé, F., Cortes, J., Schmid, P., Loirat, D., Tredan, O., Ciruelos, E., Dalenc, F., Gómez Pardo, P., et al. (2022). Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. *J. Clin. Oncol.* 40, LBA1001. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1001.
38. Li, X., and Wang, C.-Y. (2021). From bulk, single-cell to spatial RNA sequencing. *Int. J. Oral Sci.* 13, 36. <https://doi.org/10.1038/s41368-021-00146-0>.
39. Tan, R.S.Y.C., Ong, W.S., Lee, K.-H., Lim, A.H., Park, S., Park, Y.H., Lin, C.-H., Lu, Y.-S., Ono, M., Ueno, T., et al. (2022). HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. *BMC Med.* 20, 105. <https://doi.org/10.1186/s12916-022-02284-6>.
40. Schettini, F., Chic, N., Brasó-Maristany, F., Paré, L., Pascual, T., Conte, B., Martínez-Sáez, O., Adamo, B., Vidal, M., Barnadas, E., et al. (2021). Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. *npj Breast Cancer* 7, 1. <https://doi.org/10.1038/s41523-020-00208-2>.
41. Vidula, N., Yau, C., and Rugo, H. (2022). Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. *Breast Cancer Res. Treat.* 194, 569–575. <https://doi.org/10.1007/s10549-022-06660-x>.
42. Ambrogio, F., Fornili, M., Boracchi, P., Trerotola, M., Relli, V., Simeone, P., La Sorda, R., Lattanzio, R., Querzoli, P., Pedriali, M., et al. (2014). Trop-2 Is a Determinant of Breast Cancer Survival. *PLoS One* 9, e96993. <https://doi.org/10.1371/journal.pone.0096993>.
43. Aslan, M., Hsu, E.-C., Garcia-Marques, F.J., Bermudez, A., Liu, S., Shen, M., West, M., Zhang, C.A., Rice, M.A., Brooks, J.D., et al. (2021). Oncogene-mediated metabolic gene signature predicts breast cancer outcome. *npj Breast Cancer* 7, 141. <https://doi.org/10.1038/s41523-021-00341-6>.
44. Rizeq, B., Zakaria, Z., and Ouhit, A. (2018). Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression. *Cancer Sci.* 109, 33–42. <https://doi.org/10.1111/cas.13437>.
45. Kanda, Y., Mizuno, A., Takasaki, T., Satoh, R., Hagihara, K., Masuko, T., Endo, Y., Tanabe, G., and Sugiura, R. (2021). Down-regulation of dual-specificity phosphatase 6, a negative regulator of oncogenic ERK signaling, by ACA-28 induces apoptosis in NIH/3T3 cells overexpressing HER2/ErbB2. *Gene Cell.* 26, 109–116. <https://doi.org/10.1111/gtc.12823>.
46. Desai, K., Nair, M.G., Prabhu, J.S., Vinod, A., Korlimarla, A., Rajarajan, S., Aiyappa, R., Kaluve, R.S., Alexander, A., Hari, P.S., et al. (2016). High expression of integrin β 6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers. *Cancer Med.* 5, 2000–2011. <https://doi.org/10.1002/cam4.756>.
47. Cheung, K.J., Gabrielson, E., Werb, Z., and Ewald, A.J. (2013). Collective invasion in breast cancer requires a conserved basal epithelial program. *Cell* 155, 1639–1651. <https://doi.org/10.1016/j.cell.2013.11.029>.
48. Seol, H., Lee, H.J., Choi, Y., Lee, H.E., Kim, Y.J., Kim, J.H., Kang, E., Kim, S.-W., and Park, S.Y. (2012). Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. *Mod. Pathol.* 25, 938–948. <https://doi.org/10.1038/modpathol.2012.36>.
49. Janiszewska, M., Liu, L., Almdroff, V., Kuang, Y., Paweletz, C., Sakr, R.A., Weigelt, B., Hanker, A.B., Chandarlapaty, S., King, T.A., et al. (2015). In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. *Nat. Genet.* 47, 1212–1219. <https://doi.org/10.1038/ng.3391>.
50. Soucheray, M., Capelletti, M., Pulido, I., Kuang, Y., Paweletz, C.P., Becker, J.H., Kikuchi, E., Xu, C., Patel, T.B., Al-Shahrour, F., et al. (2015). Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. *Cancer Res.* 75, 4372–4383. <https://doi.org/10.1158/0008-5472.can-15-0377>.
51. Muzumdar, M.D., Dorans, K.J., Chung, K.M., Robbins, R., Tammela, T., Gocheva, V., Li, C.M.-C., and Jacks, T. (2016). Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. *Nat. Commun.* 7, 12685. <https://doi.org/10.1038/ncomms12685>.
52. Liu, B., Li, C., Li, Z., Wang, D., Ren, X., and Zhang, Z. (2020). An entropy-based metric for assessing the purity of single cell populations. *Nat. Commun.* 11, 3155. <https://doi.org/10.1038/s41467-020-16904-3>.
53. Sheffer, M., Lowry, E., Beelen, N., Borah, M., Amara, S.N.-A., Mader, C.C., Roth, J.A., Tsherniak, A., Freeman, S.S., Dashevsky, O., et al. (2021). Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. *Nat. Genet.* 53, 1196–1206. <https://doi.org/10.1038/s41588-021-00889-w>.
54. Baretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 483, 603–607. <https://doi.org/10.1038/nature11003>.
55. Network, N.C.C. (2022). Breast Cancer, (v4.2022). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
56. Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. *Nat. Rev. Cancer* 12, 252–264. <https://doi.org/10.1038/nrc3239>.
57. Nanda, R., Liu, M.C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A.J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020). Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. *JAMA Oncol.* 6, 676–684. <https://doi.org/10.1001/jamaoncol.2019.6650>.
58. Wu, N.C., Wong, W., Ho, K.E., Chu, V.C., Rizo, A., Davenport, S., Kelly, D., Makar, R., Jassem, J., Duchnowska, R., et al. (2018). Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKI67) by RT-qPCR on an automated, broadly deployed diagnostic platform. *Breast Cancer Res. Treat.* 172, 327–338. <https://doi.org/10.1007/s10549-018-4889-5>.
59. Denkert, C., Huober, J., Loibl, S., Prinzel, J., Kronenwett, R., Darb-Esfahani, S., Brase, J.C., Solbach, C., Mehta, K., Fasching, P.A., et al. (2013). HER2 and ESR1 mRNA expression levels and response to neoadjuvant

- trastuzumab plus chemotherapy in patients with primary breast cancer. *Breast Cancer Res.* 15, R11. <https://doi.org/10.1186/bcr3384>.
60. Wang, Z., Portier, B.P., Gruver, A.M., Bui, S., Wang, H., Su, N., Vo, H.-T., Ma, X.-J., Luo, Y., Budd, G.T., and Tubbs, R.R. (2013). Automated Quantitative RNA in Situ Hybridization for Resolution of Equivocal and Heterogeneous ERBB2 (HER2) Status in Invasive Breast Carcinoma. *J. Mol. Diagn.* 15, 210–219. <https://doi.org/10.1016/j.jmoldx.2012.10.003>.
 61. Press, M.F., Finn, R.S., Cameron, D., Di Leo, A., Geyer, C.E., Villalobos, I.E., Santiago, A., Guzman, R., Gasparyan, A., Ma, Y., et al. (2008). HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. *Clin. Cancer Res.* 14, 7861–7870. <https://doi.org/10.1158/1078-0432.Ccr-08-1056>.
 62. Kurozumi, S., Yamaguchi, Y., Matsumoto, H., Inoue, K., Kurosumi, M., Oyama, T., Horiguchi, J., Fujii, T., and Shirabe, K. (2019). Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer. *Med. Mol. Morphol.* 52, 90–98. <https://doi.org/10.1007/s00795-018-0206-y>.
 63. Vassilakopoulou, M., Togun, T., Dafni, U., Cheng, H., Bordeaux, J., Neumeister, V.M., Bobos, M., Pentheroudakis, G., Skarlos, D.V., Pectasides, D., et al. (2014). In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. *PLoS One* 9, e99131. <https://doi.org/10.1371/journal.pone.0099131>.
 64. Coates, J.T., Sun, S., Leshchiner, I., Thimmiah, N., Martin, E.E., McLoughlin, D., Danysh, B.P., Slowik, K., Jacobs, R.A., Rhrissorakrai, K., et al. (2021). Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. *Cancer Discov.* 11, 2436–2445. <https://doi.org/10.1158/2159-8290.Cd-21-0702>.
 65. Chou, J., Trepka, K., Sjöström, M., Egusa, E.A., Chu, C.E., Zhu, J., Chan, E., Gibb, E.A., Badura, M.L., Contreras-Sanz, A., et al. (2022). TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. *Eur. Urol. Oncol.* 5, 714–718. <https://doi.org/10.1016/j.euo.2021.11.005>.
 66. Ohmachi, T., Tanaka, F., Mimori, K., Inoue, H., Yanaga, K., and Mori, M. (2006). Clinical significance of TROP2 expression in colorectal cancer. *Clin. Cancer Res.* 12, 3057–3063. <https://doi.org/10.1158/1078-0432.Ccr-05-1961>.
 67. Bignotti, E., Todeschini, P., Calza, S., Falchetti, M., Ravanini, M., Tassi, R.A., Ravaggi, A., Bandiera, E., Romani, C., Zanotti, L., et al. (2010). Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. *Eur. J. Cancer* 46, 944–953. <https://doi.org/10.1016/j.ejca.2009.12.019>.
 68. Stepan, L.P., Trueblood, E.S., Hale, K., Babcook, J., Borges, L., and Sutherland, C.L. (2011). Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. *J. Histochem. Cytochem.* 59, 701–710. <https://doi.org/10.1369/0022155411410430>.
 69. Bardia, A., Rugo, H.S., Cortés, J., Tolane, S.M., Schmid, P., Motwani, M., Yoon, O.K., Boice, J., Zhuo, L., and Marmé, F. (2023). Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study. *J. Clin. Oncol.* 41, 1082. https://doi.org/10.1200/JCO.2023.41.16_suppl.1082.
 70. Rugo, H.S., Delord, J.P., Im, S.A., Ott, P.A., Piha-Paul, S.A., Bedard, P.L., Sachdev, J., Le Tourneau, C., van Brummelen, E.M.J., Varga, A., et al. (2018). Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. *Clin. Cancer Res.* 24, 2804–2811. <https://doi.org/10.1158/1078-0432.Ccr-17-3452>.
 71. Kwa, M.J., and Adams, S. (2018). Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. *Cancer* 124, 2086–2103. <https://doi.org/10.1002/cncr.31272>.
 72. Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M.J., Powell, S.F., et al. (2018). Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 378, 2078–2092. <https://doi.org/10.1056/NEJMoa1801005>.
 73. Garon, E.B., Rizvi, N.A., Hui, R., Leigh, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. *N. Engl. J. Med.* 372, 2018–2028. <https://doi.org/10.1056/NEJMoa1501824>.
 74. Schachter, J., Ribas, A., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet* 390, 1853–1862. [https://doi.org/10.1016/s0140-6736\(17\)31601-x](https://doi.org/10.1016/s0140-6736(17)31601-x).
 75. Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., et al. (2017). Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N. Engl. J. Med.* 376, 1015–1026. <https://doi.org/10.1056/NEJMoa1613683>.
 76. Cortes, J., Rugo, H.S., Cescon, D.W., Im, S.-A., Yusof, M.M., Gallardo, C., Lipatov, O., Barrios, C.H., Perez-Garcia, J., Iwata, H., et al. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. *N. Engl. J. Med.* 387, 217–226. <https://doi.org/10.1056/NEJMoa2202809>.
 77. Mittendorf, E.A., Zhang, H., Barrios, C.H., Saji, S., Jung, K.H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M.L., et al. (2020). Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. *Lancet* 396, 1090–1100. [https://doi.org/10.1016/S0140-6736\(20\)31953-X](https://doi.org/10.1016/S0140-6736(20)31953-X).
 78. Gianni, L., Huang, C.S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2022). Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. *Ann. Oncol.* 33, 534–543. <https://doi.org/10.1016/j.annonc.2022.02.004>.
 79. Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J.U., Furlanetto, J., Zahm, D.M., Hanusch, C., Thomalla, J., et al. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. *Ann. Oncol.* 33, 1149–1158. <https://doi.org/10.1016/j.annonc.2022.07.1940>.
 80. Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.U., Grischke, E.M., Furlanetto, J., Tesch, H., Hanusch, C., et al. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Ann. Oncol.* 30, 1279–1288. <https://doi.org/10.1093/annonc/mdz158>.
 81. Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y.H., Hui, R., Harbeck, N., et al. (2020). Pembrolizumab for Early Triple-Negative Breast Cancer. *N. Engl. J. Med.* 382, 810–821. <https://doi.org/10.1056/NEJMoa1910549>.
 82. Conroy, J.M., Pabla, S., Nesline, M.K., Glenn, S.T., Papanicolau-Sengos, A., Burgher, B., Andreas, J., Giamo, V., Wang, Y., Lenzo, F.L., et al. (2019). Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. *J. Immunother. Cancer* 7, 18. <https://doi.org/10.1186/s40425-018-0489-5>.
 83. Kang, S.Y., Heo, Y.J., Kwon, G.Y., and Kim, K.M. (2022). Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1

- Immunohistochemistry in Gastric and Urothelial Carcinoma. *Front. Oncol.* **12**, 856444. <https://doi.org/10.3389/fonc.2022.856444>.
84. Tretiakova, M., Fulton, R., Kocherginsky, M., Long, T., Ussakli, C., Antic, T., and Gown, A. (2018). Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. *Mod. Pathol.* **31**, 623–632. <https://doi.org/10.1038/modpathol.2017.188>.
 85. Li, Y., Vennapusa, B., Chang, C.W., Tran, D., Nakamura, R., Sumiyoshi, T., Hegde, P., and Molinero, L. (2021). Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. *Appl. Immunohistochem. Mol. Morphol.* **29**, 258–264. <https://doi.org/10.1097/pai.0000000000000857>.
 86. El Bairi, K., Haynes, H.R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J.R., Sur, D., Amendola, L.C., Gharib, M., et al. (2021). The tale of TILs in breast cancer: A report from The International Immunology Biomarker Working Group. *npj Breast Cancer* **7**, 150. <https://doi.org/10.1038/s41523-021-00346-1>.
 87. Cristescu, R., Aurora-Garg, D., Albright, A., Xu, L., Liu, X.Q., Loboda, A., Lang, L., Jin, F., Rubin, E.H., Snyder, A., and Lunceford, J. (2022). Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. *J. Immunother. Cancer* **10**, e003091. <https://doi.org/10.1136/jitc-2021-003091>.
 88. Iwase, T., Blenman, K.R.M., Li, X., Reisenbichler, E., Seitz, R., Hout, D., Nielsen, T.J., Schweitzer, B.L., Bailey, D.B., Shen, Y., et al. (2021). A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunotherapy for Primary Triple-Negative Breast Cancer. *Cancers* **13**, 4839. <https://doi.org/10.3390/cancers13194839>.
 89. Gonzalez-Ericsson, P.I., Wulfkhule, J.D., Gallagher, R.I., Sun, X., Axelrod, M.L., Sheng, Q., Luo, N., Gomez, H., Sanchez, V., Sanders, M., et al. (2021). Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. *Clin. Cancer Res.* **27**, 5299–5306. <https://doi.org/10.1158/1078-0432.Ccr-21-0607>.
 90. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47. <https://doi.org/10.1093/nar/gkv007>.
 91. Carlson, M. (2019). *org.Hs.eg.db: Genome wide annotation for Human. R package version 3.8.2*.
 92. McGinnis, C.S., Murrow, L.M., and Gartner, Z.J. (2019). DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst.* **8**, 329–337.e4. <https://doi.org/10.1016/j.cels.2019.03.003>.
 93. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., Zheng, S., Butler, A., Lee, M.J., Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e29. <https://doi.org/10.1016/j.cell.2021.04.048>.
 94. Finak, G., McDavid, A., Yajima, M., Deng, J., Gersuk, V., Shalek, A.K., Slichter, C.K., Miller, H.W., McElrath, M.J., Pric, M., et al. (2015). MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol.* **16**, 278. <https://doi.org/10.1186/s13059-015-0844-5>.
 95. Hafemeister, C., and Satija, R. (2019). Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol.* **20**, 296. <https://doi.org/10.1186/s13059-019-1874-1>.
 96. Andreatta, M., and Carmona, S.J. (2021). UCell: Robust and scalable single-cell gene signature scoring. *Comput. Struct. Biotechnol. J.* **19**, 3796–3798. <https://doi.org/10.1016/j.csbj.2021.06.043>.
 97. Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang, W., Zhan, L., et al. (2021). clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation* **2**, 100141. <https://doi.org/10.1016/j.xinn.2021.100141>.
 98. Dolgalev, I. (2022). *msigdb: MSigDB Gene Sets for Multiple Organisms in a Tidy Data Format. R package version 7*.
 99. Colaprico, A., Silva, T.C., Olsen, C., Garofano, L., Cava, C., Garolini, D., Sabetot, T.S., Malta, T.M., Pagnotta, S.M., Castiglioni, I., et al. (2016). TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res.* **44**, e71. <https://doi.org/10.1093/nar/gkv1507>.
 100. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550. <https://doi.org/10.1186/s13059-014-0550-8>.
 101. Tickle, T.T.I., Georgescu, C., Brown, M., and Haas, B. (2019). *inferCNV of the Trinity CTAT Project*.
 102. Gu, Z., Schlesner, M., and Hübschmann, D. (2021). cola: an R/Bioconductor package for consensus partitioning through a general framework. *Nucleic Acids Res.* **49**, e15. <https://doi.org/10.1093/nar/gkaa1146>.
 103. Browaeys, R., Saelens, W., and Saeys, Y. (2020). NicheNet: modeling intercellular communication by linking ligands to target genes. *Nat. Methods* **17**, 159–162. <https://doi.org/10.1038/s41592-019-0667-5>.
 104. Jin, S., Guerrero-Juarez, C.F., Zhang, L., Chang, I., Ramos, R., Kuan, C.-H., Myung, P., Plikus, M.V., and Nie, Q. (2021). Inference and analysis of cell-cell communication using CellChat. *Nat. Commun.* **12**, 1088. <https://doi.org/10.1038/s41467-021-21246-9>.
 105. Jew, B., Alvarez, M., Rahmani, E., Miao, Z., Ko, A., Garske, K.M., Sul, J.H., Pietiläinen, K.H., Pajukanta, P., and Halperin, E. (2020). Accurate estimation of cell composition in bulk expression through robust integration of single-cell information. *Nat. Commun.* **11**, 1971. <https://doi.org/10.1038/s41467-020-15816-6>.
 106. Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., and Müller, M. (2011). pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinf.* **12**, 77. <https://doi.org/10.1186/1471-2105-12-77>.
 107. Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C.P., Caramia, F., Salgado, R., Byrne, D.J., Teo, Z.L., Dushyanthen, S., et al. (2018). Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. *Nat. Med.* **24**, 986–993. <https://doi.org/10.1038/s41591-018-0078-7>.
 108. Bassez, A., Vos, H., Van Dyck, L., Floris, G., Arijis, I., Desmedt, C., Boeckx, B., Vanden Bempt, M., Nevelsteen, I., Lambein, K., et al. (2021). A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. *Nat. Med.* **27**, 820–832. <https://doi.org/10.1038/s41591-021-01323-8>.
 109. Ghandi, M., Huang, F.W., Jané-Valbuena, J., Kryukov, G.V., Lo, C.C., McDonald, E.R., Barretina, J., Gelfand, E.T., Bielski, C.M., Li, H., et al. (2019). Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* **569**, 503–508. <https://doi.org/10.1038/s41586-019-1186-3>.
 110. Pliner, H.A., Shendure, J., and Trapnell, C. (2019). Supervised classification enables rapid annotation of cell atlases. *Nat. Methods* **16**, 983–986. <https://doi.org/10.1038/s41592-019-0535-3>.
 111. Quan, F., Liang, X., Cheng, M., Yang, H., Liu, K., He, S., Sun, S., Deng, M., He, Y., Liu, W., et al. (2023). Annotation of cell types (ACT): a convenient web server for cell type annotation. *Genome Med.* **15**, 91. <https://doi.org/10.1186/s13073-023-01249-5>.
 112. Zhang, X., Lan, Y., Xu, J., Quan, F., Zhao, E., Deng, C., Luo, T., Xu, L., Liao, G., Yan, M., et al. (2019). CellMarker: a manually curated resource of cell markers in human and mouse. *Nucleic Acids Res.* **47**, D721–d728. <https://doi.org/10.1093/nar/gky900>.
 113. Crinier, A., Milpied, P., Escalière, B., Piperoglou, C., Galluso, J., Balsamo, A., Spinelli, L., Cervera-Marzal, I., Ebbo, M., Girard-Madoux, M., et al. (2018). High-Dimensional Single-Cell Analysis Identifies Organ-Specific

- Signatures and Conserved NK Cell Subsets in Humans and Mice. *Immunity* 49, 971–986.e5. <https://doi.org/10.1016/j.immuni.2018.09.009>.
114. Kim, D., Langmead, B., and Salzberg, S.L. (2015). HISAT: a fast spliced aligner with low memory requirements. *Nat. Methods* 12, 357–360. <https://doi.org/10.1038/nmeth.3317>.
115. Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31, 166–169. <https://doi.org/10.1093/bioinformatics/btu638>.
116. Durinck, S., Moreau, Y., Kasprzyk, A., Davis, S., De Moor, B., Brazma, A., and Huber, W. (2005). BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. *Bioinformatics* 21, 3439–3440. <https://doi.org/10.1093/bioinformatics/bti525>.
117. Liu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack, A.D., Kovatich, A.J., Benz, C.C., Levine, D.A., Lee, A.V., et al. (2018). An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell* 173, 400–416.e11. <https://doi.org/10.1016/j.cell.2018.02.052>.
118. Therneau, T. (2022). *A Package for Survival Analysis in R*. R package version 3.3.1.
119. Neftel, C., Laffy, J., Filbin, M.G., Hara, T., Shore, M.E., Rahme, G.J., Richman, A.R., Silverbush, D., Shaw, M.L., Hebert, C.M., et al. (2019). An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. *Cell* 178, 835–849.e21. <https://doi.org/10.1016/j.cell.2019.06.024>.
120. Zamai, L., Mariani, A.R., Zauli, G., Rodella, L., Rezzani, R., Manzoli, F.A., and Vitale, M. (1998). Kinetics of in vitro natural killer activity against K562 cells as detected by flow cytometry. *Cytometry* 32, 280–285. [https://doi.org/10.1002/\(sicj\)1097-0320\(19980801\)32:4<280::aid-cyto4>3.0.co;2-m](https://doi.org/10.1002/(sicj)1097-0320(19980801)32:4<280::aid-cyto4>3.0.co;2-m).
121. Tremblay-McLean, A., Coenraads, S., Kiani, Z., Dupuy, F.P., and Bernard, N.F. (2019). Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function. *BMC Immunol.* 20, 8. <https://doi.org/10.1186/s12865-018-0272-x>.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-huCD56 BV605, Clone HCD56 (mouse IgG1k)	BioLegend	Cat#318334; RRID: AB_2561912
Chemicals, peptides, and recombinant proteins		
4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI)	Invitrogen	Cat#D1306
Dimethyl sulfoxide (DMSO)	Sigma Aldrich	Cat#D2650
Dulbecco's Phosphate Buffered Saline (DPBS)	Sigma Aldrich	Cat#D8537
Fetal Bovine Serum (FBS)	Corning	Cat#35-011-CV
Human IL-2 IS, premium grade	Miltenyi Biotec	Cat#130-097-746
RPMI-1640	Corning	Cat#10-040-CV
Penicillin-Streptomycin (100X)	Cytiva HyClone	Cat#SV30010
Sodium Pyruvate (100 mM)	Gibco	Cat#11360070
Minimum Essential Media (MEM) non-essential amino acids (NEAA) (100X)	Gibco	Cat#11140050
GlutaMAX Supplement	Gibco	Cat#35050061
2-mercaptoethanol (50 mM)	Gibco	Cat#21985023
Critical commercial assays		
UltraComp eBeads Plus Compensation Beads	Invitrogen	Cat#01-3333-42
Deposited data		
Primary breast tumor atlas	This paper	https://doi.org/10.5281/zenodo.10672250
Experimental models: Cell lines		
NK-92	ATCC	Cat#CRL-2407, RRID: CVCL_2142
BT-474	ATCC	Cat#HTB-20, RRID: CVCL_0179
MDA-MB-436	ATCC	Cat#HTB-130, RRID: CVCL_0623
K-562	ATCC	Cat#CCL-243, RRID: CVCL_0004
Software and algorithms		
limma (v3.50.1)	Ritchie et al. ⁹⁰	https://bioconductor.org/packages/release/bioc/html/limma.html
org.Hs.e.g.,db (v3.14.0)	Carlson et al. ⁹¹	https://bioconductor.org/packages/release/data/annotation/html/org.Hs.e.g.db.html
DoubletFinder (v2.0.3)	McGinnis et al. ⁹²	https://github.com/chris-mcginnis-ucsf/DoubletFinder
Seurat (v4.1.0)	Hao et al. ⁹³	https://satijalab.org/seurat/
MAST (v1.20.0)	Finak et al. ⁹⁴	https://www.bioconductor.org/packages/release/bioc/html/MAST.html
SCTransform (v0.3.2.9008)	Hafemeister et al. ⁹⁵	https://github.com/satijalab/sctransform
UCell (v1.99.1)	Andreatta et al. ⁹⁶	https://github.com/carmonalab/UCell
clusterProfiler (v4.2.2)	Wu et al. ⁹⁷	https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html
msigdbr (v7.5.1)	Dolgalev et al. ⁹⁸	https://cran.r-project.org/web/packages/msigdbr/vignettes/msigdbr-intro.html
TCGAbiolinks (v2.18.0)	Colaprico et al. ⁹⁹	https://bioconductor.org/packages/release/bioc/html/TCGAbiolinks.html
DESeq2 (v1.34.0)	Love et al. ¹⁰⁰	https://bioconductor.org/packages/release/bioc/html/DESeq2.html
inferCNV (v.0.99.7)	Tickle et al. ¹⁰¹	https://github.com/broadinstitute/infercnv
ROGUE	Liu et al. ⁵²	https://github.com/PaulingLiu/ROGUE

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
cola (v2.0.0)	Gu et al. ¹⁰²	https://www.bioconductor.org/packages/release/bioc/html/cola.html
NicheNet (v1.1.0)	Browaeys et al. ¹⁰³	https://github.com/saeyslab/nichenetr
CellChat (v0.0.1)	Jin et al. ¹⁰⁴	https://github.com/jinworks/CellChat
BisqueRNA (v1.0.5)	Jew et al. ¹⁰⁵	https://github.com/cozygene/bisque
pROC (v1.18.0)	Robin et al. ¹⁰⁶	https://cran.r-project.org/web/packages/pROC/index.html
Other		
Resource website for the primary breast tumor atlas publication containing dataset and analyses	This paper	https://github.com/ChanLab-UTSW/BreastCancer_Integrated
Original source dataset of immune cells in primary breast tumors	Azizi et al. ⁷	GEO: GSE114727
Original source dataset of primary TNBC tumors	Karaayvaz et al. ⁸	GEO: GSE118389
Original source dataset of primary breast tumors	Pal et al. ⁹	GEO: GSE161529
Original source dataset of T cells in primary TNBC tumors	Savas et al. ¹⁰⁷	GEO: GSE110686
Original source dataset of primary breast tumors	Wu et al. ¹³	GEO: GSE176078
Original source dataset with primary breast tumors	Xu et al. ¹⁴	GEO: GSE180286
Original source dataset with primary breast tumors	Qian et al. ¹¹	https://lambrechtslab.sites.vib.be/en/pan-cancer-blueprint-tumour-microenvironment-0
Original source dataset of primary TNBC tumors	Wu et al. ¹²	https://singlecell.broadinstitute.org/single_cell/study/SCP1106/stromal-cell-diversity-associated-with-immune-evasion-in-human-triple-negative-breast-cancer
Original source dataset of PD-1 treated primary breast tumors	Bassez et al. ¹⁰⁸	https://lambrechtslab.sites.vib.be/en/single-cell
Breast cancer cell line data from DepMap 22Q2 public release	Ghandi et al. ¹⁰⁹	https://depmap.org/portal/download/all/
Spatially resolved data for 6 primary breast tumors	Wu et al. ¹²	https://doi.org/10.5281/zenodo.4739739
Spatially resolved data from 5 primary breast tumors	10x Genomics	https://www.10xgenomics.com/datasets/human-breast-cancer-ductal-carcinoma-in-situ-invasive-carcinoma-ffpe-1-standard-1-3-0 ; https://www.10xgenomics.com/datasets/human-breast-cancer-visium-fresh-frozen-whole-transcriptome-1-standard ; https://www.10xgenomics.com/datasets/human-breast-cancer-block-a-section-1-1-standard-1-1-0 ; https://www.10xgenomics.com/datasets/human-breast-cancer-whole-transcriptome-analysis-1-standard-1-2-0 ; https://www.10xgenomics.com/products/xenium-in-situ/preview-dataset-human-breast
I-SPY2-990 mRNA and clinical data for I-SPY2 trial	Nanda et al. ⁵⁷	GEO: GSE194040

RESOURCES AVAILABILITY

Lead contact

Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Dr. Isaac S. Chan (isaac.chan@utsouthwestern.edu).

Materials availability

This study did not generate new unique reagents.

Data and code availability

- Single-cell RNA-seq data have been deposited at GEO and are publicly available as of the date of publication. Accession numbers are listed in the [key resources table](#).
- All original code will be deposited at https://github.com/ChanLab-UTSW/BreastCancer_Integrated and is publicly available as of the date of publication. DOIs are listed in the [key resources table](#).
- Any additional information required to reanalyze the data reported in this work paper is available from the [lead contact](#) upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

NK-92

NK-92 cells are a human NK cell line derived from a 50-year-old male with malignant non-Hodgkin's lymphoma. These cells were cultured in RPMI-1640 with 10% FBS, 1% penicillin-streptomycin, 1% sodium pyruvate, 1% MEM-NEAA, 1% GlutaMAX, 0.01% 2-mercaptoethanol, and 100 IU/mL of human IL-2 at 37°C and 5% CO₂.

BT-474

BT-474 cells are a human mammary duct cell line derived from a 60-year-old female with invasive ductal carcinoma. These cells were cultured in RPMI-1640 with 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO₂.

MDA-MB-436

MDA-MB-436 cells are a human mammary gland cell line derived from a 43-year-old female with adenocarcinoma. These cells were cultured in RPMI-1640 with 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO₂.

K-562

K-562 cells are a human bone marrow-derived lymphoblastic cell line from a 53-year-old female with chronic myelogenous leukemia. These cells were cultured in RPMI-1640 with 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO₂.

NK-92 cell line media was used in all coculture conditions.

Cell line authentication was performed at the UT Southwestern DNA Genotypic Core facility.

METHOD DETAILS

Processing of single-cell RNA-seq datasets

We obtained 119 primary breast tumor samples across 8 publicly available datasets from 88 untreated female patients 32 to 90 years of age. All gene names were converted to the official gene alias by the HUGO Gene Nomenclature Committee (HGNC) using *limma* (v3.50.1) and *org.Hs.e.g.,db* (v3.14.0) packages.^{90,91} Cells were filtered by percent mitochondrial transcripts, percent hemoglobin genes, number of RNA molecules, and number of features. In brief, cells below the 5th percentile and above the 95th percentile of each metric were removed, as well as cells with over 15% mitochondrial content. We used the *DoubletFinder* (v2.0.3) package to identify and remove doublets from the dataset.⁹² Doublet rates were estimated using reported rates from the original technology used and cell loadings provided by original studies.

Integration of primary breast tumor datasets

119 untreated primary samples were integrated via reference-based integration using *Seurat* (v4.1.0) to remove batch effects. To prevent over-correction, *SCTransform* (v0.3.2.9008) was used.⁹⁵ The 10x datasets were chosen as the reference and *rann* was chosen for *FindNeighbors*. Success of batch effect correction was determined by ensuring that no single technology, cohort, or subtype was driving any clusters (Figures S1D–S1L, S2A–S2I; Data S8).

Cell type annotation and clustering

Initial cell type annotations were identified using canonical and literature-derived cell markers as specified in Data S2.^{96,110–113} Three methods were used to refine the annotations. The first utilized cluster-level annotations via the *UCell* (v1.99.1) package⁹⁶; the second labeled cells based on thresholds of number of markers, and then clustered and calculated the average expression of those markers to refine the cell identities⁸; the third took highest average expression of select markers. The annotation with highest agreement across the three methods was selected. If all methods disagreed, the cluster-level annotation was chosen.

For the cluster-level method, all cell markers were aggregated into a single score using the *AddModuleScore_UCell* function from the *UCell* (v1.99.1) package.^{93,96} Clusters with the highest score for a given cell type were labeled, isolated, and re-integrated to account for batch effects. Subtype-specific cell markers were applied (e.g., *CD4* for CD4⁺ T cells).

For the second method, cell type annotations were identified based on the number of cell type markers with non-zero expression for a given cell. In brief, epithelial cells labeled if they had two epithelial markers or at least one of *EPCAM*, *KRT8*, *KRT18*, or *KRT19*. Immune cells were labeled if they had at least two markers of that immune cell type and no other type, *PTPRC* and at least one marker

of that type and no other, or at least three markers for that type and at most one marker of a different immune type. Stromal cells were labeled if they had only cell-type-specific markers or at least three cell-type-specific markers and at most one endothelial marker. Finally, endothelial cells were labeled if they had only endothelial markers or at least three endothelial markers and at most one marker associated with a stromal cell type.

Lastly, we examined log-normalized expression values of the selected cell type markers for each cell. Each cell was annotated with the cell type that had the highest average expression for their markers across all features. T and myeloid subsets were identified in the same manner once the cells were identified as T cells or myeloid cells respectively.

The final cell call was determined based on the highest consensus or defaulted to the cluster-level annotation. Of the 116,346 cells which had original source annotations, 93% had concordant annotations between the original source and our analysis (Data S7).

Identification of natural killer cell subsets

The NK cell cluster was isolated and re-integrated (Figure S4A). Given the higher dimensionality of the dataset containing only NK cells (i.e., number of features \gg number of NK cells), the Manhattan distance metric was used. *FindMarkers* in *Seurat* (v4.1.0) and *MAST* (v1.20.0) were used to identify differentially expressed genes for each cluster, with absolute \log_2 fold change (\log_2FC) cutoff of 0.56 (Bonferroni adjusted p value <0.05).^{93,94} Marker genes for each NK cell subset are included in Table 1.

To identify human tumor-promoting rNK cells, we previously developed a gene signature based on genes upregulated in tumor-exposed NK cells compared to healthy NK cells in MMTV-PyMT and WT FVB/n mice.²⁰ In our prior study, primary healthy and tumor-exposed NK cells were isolated, and total RNA was extracted and sequenced using Illumina NextSeq 500. Bulk RNA-seq paired-end reads were aligned and mapped using *hisat2*¹¹⁴ and *HTSeq*¹¹⁵ respectively, and *DESeq2* was used for differential gene expression analysis. In the current study, mouse genes were converted into their human aliases using *BioMart* (v2.50.0).¹¹⁶ Because the MMTV-PyMT mouse strain used in the previous study most closely resembles the luminal A/luminal B and basal subtypes, these subtypes were first analyzed for the presence of rNK cells. NK cells in the top 75th percentile for the 90-gene signature were labeled as rNK cells. We identified 841 total rNK cells in the integrated dataset.

Gene set enrichment analysis across the NK cell subsets was performed using *clusterProfiler* (v4.2.2) and the Hallmark gene set collection from *msigdb* (v7.5.1).^{97,98} Only genes with $\log_2FC > 0$ were considered. Samples with fewer than 10 NK cells were omitted. For visualization of differentially expressed genes, the \log_2FC cutoff was increased to 1.5 and a false discovery rate (FDR) cutoff was set to 0.05. To examine expression of the rNK signature within NK cell subsets and across clinical subtypes, Kruskal-Wallis and pairwise post-hoc Dunn tests were performed. For similarity analysis of rNK cells, the expression matrix was reduced to genes in the rNK cell signature, and the Pearson correlation coefficient was calculated for all pairwise combinations of rNK cells with rNK cells and for rNK cells with non-rNK cells. These analyses were also stratified by age to ensure that age was not a confounder (Figures S5D–S5F).

Survival analysis

To assess survival outcomes, we obtained the primary solid tumor samples from the breast cancer cohort of The Cancer Genome Atlas (TCGA).¹¹⁷ Expression data was normalized using *TCGAbiolinks* (v2.18.0) package and transformed using *DESeq2* (v1.34.0) with default parameters.^{99,100} For all breast cancer samples, we applied NK-specific genes (*NCAM1*, *FGFBP2*, *KLRD1*, *FCGR3A*, *KLRK1*) and the 44 upregulated genes of the rNK signature. Of the 1,098 total patients in the dataset, we labeled the top 300 patients with highest rNK signature expression as ‘rNK-high,’ and the remaining 798 patients were labeled as ‘rNK-low.’ Next, we selected samples with high fraction of tumor-infiltrating NK cells (activated or resting NK cells predicted to be greater than a relative fraction of 0.015 of tumor-infiltrating immune cells in the sample), as determined by Xu et al.¹⁴ This selected 349 patients for the survival analysis (excluded 749 patients with low NK cell infiltrate). Kaplan-Meier survival curves were generated using *survival* (v2.44-1.1)¹¹⁸ and assessed using log rank test statistics. Patients ≥ 45 yo demonstrated worse outcomes with increased rNK cell signature expression ($p < 0.05$) (Figure S5F); survival analysis for patients <45 yo did not show significance, though there was a similar trend. To ensure age was not a confounder, correlation between age at initial diagnosis and survival was also assessed ($R = -0.11$, $p > 0.05$) (Figure S5E).

Identification of epithelial cell clusters

Epithelial cells were re-clustered and re-integrated to account for batch effects (Figures S6A–S6C). Copy number variant (CNV) profile analysis was used for cancer (malignant) versus normal (non-malignant) assignments. The CNV signal for individual cells was estimated using *inferCNV* (v.0.99.7) with a 100-gene sliding window; genes with mean count less than 0.1 across all cells were filtered out, and the signal was denoised using a dynamic threshold of 1.3 s.d. from the mean.¹⁰¹ Non-T cell immune cells were used for the reference cell profiles. Epithelial cells were classified as normal (non-malignant), cancer (malignant), or unassigned using a previously described method.¹¹⁹ Briefly, inferred changes at each genomic locus were scaled (between -1 and $+1$) and the mean of the squares of these values was used to define a CNV signal for each cell. For each sample, an average CNV profile was created, and each cell in the sample was then correlated to this profile for the CNV correlation score. Epithelial cells were classified cancer vs. normal based on CNV signal and CNV correlation, with thresholds of 0.4 for CNV correlation and 0.02 for CNV signal (Figures S3A–S3B). This assigned 75,883 cancer, 3,524 normal, and 4,997 unassigned epithelial cells.

Within cancer epithelial cells, *ERBB2*-positive and *TACSTD2*-positive cells were chosen due to clinical relevance. *ERBB2* and *TACSTD2* expression levels are calculated using *UCell* (v1.99.1)⁹⁶. *ERBB2*^{Hi} cells were defined by *ERBB2* expression above the 97.5th percentile of all cells, *ERBB2*^{Med} cells by expression at or below the 97.5th percentile, and *ERBB2*^{Lo} cells by zero expression.

TACSTD2^{Hi} cells were defined by positive *TACSTD2* expression above the 95th percentile of all cells, *TACSTD2*^{Med} cells by expression at or below the 95th percentile, and *TACSTD2*^{Lo} cells by zero expression. *FindMarkers* in *Seurat* (v4.1.0) and *MAST* (v1.20.0) were used to identify differentially expressed genes (>5 cells per cluster, detected in >20% of cells in a cluster, log₂FC cutoff of 1.5, FDR cutoff of 0.05).^{93,94} Gene set enrichment analysis was performed using *clusterProfiler* (v4.2.2) and the Hallmark gene set collection from *msigdb* (v7.5.1),^{97,98} using a 0.1 cutoff for absolute difference in percent expression between the pairwise populations. Expression levels of clinically actionable targets for each subset of cells was estimated by *AverageExpression* by *Seurat* (v4.1.0).⁹³ For visualization of differentially expressed genes (Figures S6H–S6K), log₂FC cutoff of 1.5 and FDR cutoff of 0.05 were used. To explore associations with clinical features, linear regression and Pearson correlations were calculated between the proportion of *ERBB2*-positive or *TACSTD2*-positive cells per sample and age or nodal status, and these analyses were stratified by subtype in Figures S7A–S7C. We additionally explored associations between % *TACSTD2*⁺ cells and nodal status in each cohort and then combined the results using Fisher's combined probability test, which was found to not be statistically significant (Figure S7C; Fisher's combined probability $X = 11.227$, $p = 0.08$). In contrast, for the integrated dataset, there was a statistically significant association between % *TACSTD2*⁺ cells per sample and nodal across all samples with nodal status clinical data ($p < 0.05$, $n = 38$).

Molecular subtype of samples using SCSubtype

To identify molecular breast cancer subtypes, we used the SC50 subtype gene signature described in Wu et al.¹³ In brief, the mean read counts for each signature were determined and the highest mean was assigned as the subtype for that cell. To determine the molecular subtype for each tumor, we determined the number of cells classified under each SC50 subtype, and then selected the subtype with the highest number of cells to be the tumor molecular subtype, following the method of Wu et al.¹³

Cancer epithelial cell heterogeneity analysis

For each tumor sample with over 50 cancer epithelial cells, heterogeneity was assessed using ROGUE, an entropy-based statistic that enables accurate and sensitive assessment of cluster purity.⁵² To identify samples with discordance between heterogeneity as characterized by the ROGUE score versus by molecular subtype, we calculated the difference between the normalized ROGUE score and the highest percentage of cells of a single subtype. Samples with difference over 50% were determined to be discordant.

To identify gene expression patterns across cancer epithelial cells, unsupervised clustering and supervised classification of all cancer epithelial cells for tumor samples with more than 50 cancer epithelial cells were performed. We generated an exhaustive collection of gene signatures that reflect molecular features of different cancer epithelial cells.

For unsupervised clustering, cancer epithelial cells were clustered at 15 resolutions (0.01, 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 1.0, 1.3, 1.6, 1.8, 2.0) utilizing *Seurat* (v4.1.0).⁹³ *FindMarkers* in *Seurat* (v4.1.0) and *MAST* (v1.20.0) were used to identify differentially expressed genes (>5 cells per cluster, only test genes with >25% difference in the fraction of detection between the clusters, log₂FC > 0.25).^{93,94} Dataset-wide unsupervised clustering returned 519 gene signatures. Unsupervised clustering was also performed on the sample level, which returned 5,546 gene signatures.

For supervised classification by SC50 molecular subtype, cancer epithelial cells were grouped by SC50 subtype.¹³ *FindMarkers* in *Seurat* (v4.1.0) and *MAST* (v1.20.0) were then used to identify differentially expressed genes in each group (>5 cells per group, only test genes detected in >20% of cells in a group, log₂FC > 0.1).^{93,94} Supervised classification based on SC50 molecular subtype returned 4 gene signatures.

For supervised classification based on clinical therapeutic targets, expression of 12 clinical therapeutic targets was considered: *ESR1*, *ERBB2*, *ERBB3*, *PIK3CA*, *NTRK1/NTRK2/NTRK3*, *CD274*, *EGFR*, *FGFR1/FGFR2/FGFR3/FGFR4*, *TACSTD2*, *CDK4/CDK6*, *AR*, and *NECTIN2*. Cancer epithelial cells grouped based on high (expression level above the 90th percentile), medium (expression level below the 90th percentile but non-zero), and low (no or zero expression) expression of clinical targets. *FindMarkers* in *Seurat* (v4.1.0) and *MAST* (v1.20.0) were then used to identify differentially expressed genes in each group (>5 cells per group, only test genes detected in >20% of cells in a group, log₂.^{93,94} Supervised classification based on clinical target expression returned 32 gene signatures.

The 12 clinical therapeutic targets were selected based on availability of corresponding therapeutic agents that are approved or under clinical development for the treatment of breast cancer. *ESR1* encodes estrogen receptor, the target for hormone therapies such as selective estrogen receptor modulators (e.g., tamoxifen) and selective estrogen receptor degraders (e.g., fulvestrant). *ERBB2* encodes HER2, the target for anti-HER2 therapies (e.g., trastuzumab, margetuximab, pertuzumab) and ADCs (e.g., trastuzumab-deruxtecan, T-DM1). *ERBB3* encodes HER3, the target for anti-HER3 monoclonal antibodies (e.g., patritumab, seribantumab, lumretuzumab), bispecific antibodies (e.g., EGFR/HER3 duligotuzumab, HER2/HER3 zenocutuzumab, HER3/IGF-1R isitarumab), and ADCs (e.g., patritumab deruxtecan), all currently under clinical development. *PIK3CA* encodes PI3 kinase, the target for PI3K inhibitors (e.g., alpelisib). *NTRK1*, *NTRK2*, and *NTRK3* are genes involved in chromosomal rearrangements (*NTRK* fusions) targeted by TRK inhibitors (e.g., larotrectinib, entrectinib). *CD274* encodes PD-L1, the target for PD-L1 inhibitors (e.g., atezolizumab, durvalumab) and PD-1 inhibitors (e.g., pembrolizumab). *EGFR* encodes the EGFR protein, the target for small molecule inhibitors (e.g., lapatinib, gefitinib, erlotinib, osimertinib) and monoclonal antibodies (e.g., cetuximab, panitumumab). *FGFR1*, *FGFR2*, *FGFR3*, and *FGFR4* encode fibroblast growth factor receptors, targeted by pan-FGFR tyrosine kinase inhibitors (e.g., AZD-4547, futibatinib, erdafitinib) currently under clinical development. *TACSTD2* encodes TROP2, the target for anti-TROP2 ADCs (e.g., sacituzumab govitecan). *CDK4* and *CDK6* encode the cyclin-dependent kinases 4 and 6, the targets for CDK4/6 inhibitors (e.g.,

abemaciclib, palbociclib, and ribociclib). *AR* encodes the androgen receptor (AR), the target for AR inhibitors (e.g., enzalutamide), CYP17 inhibitors which inhibit production of androgens (e.g., abiraterone, seviteronel), and selective androgen receptor modulators or SARMs (e.g., enobosarm or GTx-024). *NECTIN2* encodes NECTIN2 or CD112, which binds TIGIT on T and NK cells and is the target for anti-TIGIT monoclonal antibodies (e.g., tiragolumab, ociperlimab, pembrolizumab/vibostolimab) which are currently under investigation.

Only gene signatures containing over 20 genes were kept. Additionally, signature redundancy was reduced by comparing all unsupervised gene signatures and removing pairs with Jaccard similarity index >0.9. A total of 1,101 gene signatures were generated.

Consensus clustering of the Jaccard similarities between gene signatures (using spherical k-means clustering, metric ATC, implemented with *cola* (v2.0.0)) was used to identify 10 groupings (Figures S8A–S8B).¹⁰² For each grouping, we took the top 100 genes with highest frequency of occurrence across clusters. These were defined as a ‘gene element’ (GE) and were named GE1 to GE10. GE signature expression was calculated for each cancer epithelial cell using *UCell* (v1.99.1).⁹⁶ GE signature expression was Z score normalized across all cancer epithelial cells, and cells were assigned to the GE with the highest z-scored expression.

Receptor-ligand pairing analysis

To identify interactions that may influence NK cell reprogramming, *NicheNet* analyses were run between rNK cells and cancer epithelial cells separated by clinical subtype. rNK cells were set as the ‘sender’ population, and non-rNK cells were set as the ‘reference’.¹⁰³ Receptor-ligand regulatory potential scores for the top 50 predicted ligands and top 200 predicted targets were calculated and for each predicted receptor-ligand pair, an R-L interaction score was calculated as a product of ligand expression (fold change in average expression of the ligand in cancer epithelial cells of that clinical subtype) and receptor expression (percent of the rNK population that has positive expression of the receptor). For the top 20 R-L pairs selected based on this interaction score, *circos* plots were generated.

To identify interactions between cancer epithelial cells and interacting cells (i.e., CD4⁺ T cells, CD8⁺ T cells, regulatory T cells, B cells, plasma cells, myeloid cells, mast cells, MDSCs, NK cells, rNK cells, fibroblasts, myoepithelial cells, endothelial cells, perivascular-like cells), receptor-ligand pairing analysis was performed using *NicheNet* (v1.1.0) and *CellChat* (v0.0.1).^{103,104} For each GE, separate *NicheNet* analyses were run between cancer epithelial cells assigned to that GE (‘sender’) and each interacting cell population (‘receiver’). The top 50 predicted ligands and top 200 predicted targets were used for the R-L interaction score, which was the product of ligand expression (fold change in average expression on cancer epithelial cells with high vs. low GE expression) and receptor expression (percent of the interacting cell subset with positive receptor expression). For the top 20 receptor-ligand pairs selected based on this R-L interaction score, *circos* plots were generated. In addition to *NicheNet* analysis, cancer epithelial cell and interacting cell communication analysis was conducted using *CellChat* (v0.0.1) using default parameters.¹⁰⁴ For each GE, the cell-cell communication network between GE-labeled cancer epithelial cells and interacting cells was visualized using *CellChat* (v0.0.1) (104). Receptor-ligand pairings with significant (Bonferroni adjusted p value <0.05) probability of interaction were selected as a curated list.

The number of curated receptor-ligand interactions for each GE and interacting cell population was used to infer the degree of interaction between the GEs and interacting cell populations. First, the entire list of R-L interactions predicted by *NicheNet* was filtered. For each interacting cell population, the top 2,000 predicted R-Ls were selected based on *NicheNet* prediction for regulatory potential. Then, of those selected pairs, the top 400 predicted R-Ls for each GE were selected based on ligand expression (fold change in average expression of the ligand on cancer epithelial cells with high vs. low GE expression). Lastly, all overlapping R-L interactions that were predicted by both *NicheNet* and *CellChat* for a GE and interacting cell pair were selected. We combined the list of overlapping R-L interactions and the list of selected *NicheNet* R-L interactions to generate a list of curated R-L interactions for each GE and interacting cell population. For each GE and interacting cell pair, the number of curated R-L interactions was normalized across each interacting cell pair. This scaled number of R-L interactions was used to infer the degree of interaction between the GE and the interacting cell population. We visualized the scaled number of curated receptor-ligand interactions in our GE-immune interaction decoder matrix (Figure 3E). We also visualized the absolute number of curated receptor-ligands between each GE and interacting cell (Figure S8D).

Breast cancer cell line exploration

To explore cancer epithelial cell heterogeneity and NK cell sensitivity, we obtained bulk RNA-seq data from the Broad Cancer Cell Line Encyclopedia (CCLE) DepMap portal for human breast cancer cell lines.^{53,54} Bulk RNA-seq data from CCLE containing TPM values of protein-coding genes were inferred using the RSEM tool and loaded into *Seurat* (v.4.1.0) and log-normalized.^{13,93} For each cell line, GE expression was calculated by the *UCell* (v1.99.1) score of the 100-gene GE signature. For each GE, *UCell* (v1.99.1) scores were Z score normalized across all breast cancer cell lines.

We experimentally confirmed NK cell cytotoxicity against select human breast cancer cell lines. We selected the BT-474 cell line which had increased expression of NK-resistant GEs (GE1 and GE6) and the MDA-MB-436 cell line which had decreased expression of NK-resistant GEs. Additionally, the K562 cell line (derived from human myelogenous leukemia) is known to be sensitive to NK cell killing and therefore served as a positive control.^{53,120,121} The NK-92 cell line, a highly cytotoxic NK cell line, was cultured in media with IL-2. To determine killing function of NK cells against cancer cell lines, BT-474, MDA-MB-436, and K562 cells were cocultured with NK-92 cells at a ratio of 1:2 in 96-well round-bottom plates (50,000 cancer cells per well and 100,000 NK-92 cells per well) for 24 h at 37°C. Cells were stained for CD56 (BV605, Clone HCD56, Biolegend 318334) and DAPI in DPBS with 3% FBS. FACS analysis was

performed on the Cytex Aurora. Higher NK cytotoxicity was inferred based on increased % DAPI+ in CD56-negative cancer cells.

From Sheffer et al.,⁵³ breast cancer cell line sensitivity to NK cell killing was assessed using reported 24-h AUC values. Briefly, Sheffer et al. performed a PRISM-based phenotypic screen with pools of DNA-barcoded cell lines to quantify NK cell cytotoxicity against cancer cell lines using the AUC of tumor cell survival. Please refer to the original study⁵³ for additional information. For breast cancer cell lines, NK cell sensitivity was based on the reported 24-h AUC values from the Sheffer et al. study. Spearman correlation was used to assess the relationship between GE expression and NK cell sensitivity for breast cancer cell lines.

Spatial transcriptomics analysis

Processed spatial transcriptomics count matrices for 6 samples from Wu et al. and 5 samples from 10x were loaded into *Seurat* (v.4.1.0).^{13,93} We deconvoluted the underlying composition of cell types using the anchor-based Seurat integration workflow (Figure S9A). The resulting annotations calculated the fraction of each cell type per given spot and mapped the spatial distribution of cell types, which we further corroborated by the spatial expression of marker genes (Data S2). Spots labeled as normal tissue or artifact by pathologist annotation were excluded.

To investigate interactions between cancer epithelial cells and immune or stromal cells, spots were first filtered based on presence of cancer epithelial cells (spots with less than 10% predicted cancer epithelial cells excluded).⁹³ Each spot containing cancer epithelial cells was scored for expression of each of the 10 GEs using *UCell* (v1.99.1).⁹⁶ For immune and stromal cell populations, spots were filtered based on presence of their respective cell types (spots with 0% predicted cells excluded).⁹³ Each spot containing the respective cell type was scored for expression of that cell using canonical and literature-derived cell markers (Data S2). To assess colocalization, Pearson correlations were computed across spots containing between the expression of each GE and the expression of CD8⁺ T cell markers. For cell signaling predictions between select GE ligands and CD8⁺ T cell receptors, R-L co-localization scores were defined as the product of the ligand and receptor normalized expression levels.

Development of InteractPrint

For each sample, the average expression of each GE was calculated as the average of the scaled *UCell* (v1.99.1) (scaled across all cancer epithelial cells in the dataset) score.⁹⁶ Next, the number of curated R-L pairs in the GE-immune decoder matrix between each GE and CD8⁺ T cells was used to infer the degree of interaction between cancer epithelial cells and CD8⁺ T cells. GE1, GE6, GE7, GE8, and GE9 were designated as “inactivating” based on the presence inactivating CD8⁺ T cell receptors (e.g., *NECTIN2_TIGIT*) in the list of curated receptor-ligand interactions for those GEs.

T cell InteractPrint was calculated as the average of the number of curated CD8⁺ T cell R-L interactions in the GE-immune interaction decoder matrix, weighted by average expression of each GE and a factor of -1 for inactivating GEs.

$$IP = \sum_{i=1}^{10} (e_i)(R_i)(w)$$

InteractPrint = Weighted CD8⁺ T cell interaction score for a patient’s tumor

i = GE (ranges from 1 to 10)

e_i = Average GE expression (average of Z score normalized *UCell* scores for the GE across all cancer epithelial cells in the sample)

R_i = Number of curated R-L pairs (from GE-immune interaction decoder matrix)

w = Multiplier for activating or inactivating GE ($w = 1$ for CD8⁺ T cell activating GEs; $w = -1$ for CD8⁺ T cell inactivating GEs)

Validation of InteractPrint

To assess the predictive value of the T cell InteractPrint, we applied our method to a publicly available scRNA-seq dataset containing 29 primary breast tumors from patients who received pembrolizumab (Bassez et al.).¹⁰⁸ In Bassez et al., response was inferred based on T cell clonal expansion, as determined by sTCR-seq of pre- and on-treatment samples.¹⁰⁸ To determine cancer epithelial cells in the Bassez et al. dataset, CNV analysis was performed (Figures S3C–S3D). GE signature expression and T cell InteractPrint were calculated for each pre-treatment sample.

We applied our method to the I-SPY2 microarray dataset containing 69 primary breast tumors from patients who received combination paclitaxel and pembrolizumab.⁵⁷ The data was loaded using *limma* (v3.15), and the batch-corrected and normalized expression data provided by the authors was inserted into the object.⁹⁰ Genes names were converted using the same method described in the scRNA-seq processing section. Microarray data was deconvoluted with *BisqueRNA* (v1.0.5) using marker-based devolution with the 10 GE signatures to estimate the relative abundance of the GEs within each sample.¹⁰⁵ GE signature expression and T cell InteractPrint were compared for responders and non-responders.

On both datasets, we assessed the predictive value of the T cell InteractPrint compared to average expression levels of PD-L1 on cancer epithelial cells. ROC curves and AUC statistics were generated using the *pROC* (v1.18.0).¹⁰⁶ Bootstrap method ($n = 10,000$) in *pROC* (v1.18.0) was used for significance testing between T cell InteractPrint ROC and PD-L1 ROC curves.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical significance was determined using the Wilcoxon Rank-Sum test unless otherwise stated in the figure legend. Where appropriate, p values were adjusted using the Bonferroni correction where appropriate for multiple testing, unless otherwise stated in the figure legend. All boxplots depict the first and third quartiles as the lower and upper bounds, respectively. The whiskers represent 1.5x the interquartile range, and the center depicts the median. All statistical tests with statistical parameters used are defined in the figure legends; p values <0.05 were considered significant.